Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год
Применить Всего найдено 9483. Отображено 100.
02-02-2012 дата публикации

Compositions and methods for treating or preventing inflammatory bowel disease and colon cancer

Номер: US20120027799A1
Автор: Cynthia L. Sears, Drew M. Pardoll, Franck Housseau, Shaoguang Wu
Принадлежит: JOHNS HOPKINS UNIVERSITY

The invention provides compositions and methods for useful for the diagnosis of inflammatory bowel disease, ETBF-induced colitis, colonic hyperplasia and/or colon carcinogenesis in a subject in biological samples (e.g., stool, urine, blood, serum, tissue). The invention further provides compositions and methods for the treatment or prevention of colitis, colon cancer, or inflammatory bowel disease (e.g., Crohn's disease).

Подробнее
Номер записи: 1
16-02-2012 дата публикации

Anti-Hemagglutinin Antibody Compositions And Methods Of Use Thereof

Номер: US20120039899A1
Автор: Andres G. Grandea, III, Christina L. Boozer, Ole Olsen
Принадлежит: Theraclone Sciences Inc

The present invention provides novel human anti-Influenza antibodies and related compositions and methods. These antibodies are used in the prevention, inhibition, neutralization, diagnosis, and treatment of influenza infection.

Подробнее
Номер записи: 2
22-03-2012 дата публикации

Humanized antibodies against west nile virus and therapeutic and prophylactic uses thereof

Номер: US20120070429A1
Автор: Leslie S. Johnson, Ling Huang
Принадлежит: Macrogenics Inc

The present invention relates to compositions comprising humanized antibodies or fragments thereof that immunospecifically bind to one or more antigens of a flavivirus, particularly of West Nile Virus (WNV) and methods for preventing, treating or ameliorating symptoms associated with a flavivirus, particularly of West Nile Virus (WNV) infection utilizing said compositions. In particular, the present invention relates to methods for preventing, treating or ameliorating symptoms associated with WNV infection, said methods comprising administering to a human subject an effective amount of one or more humanized antibodies or fragments thereof that immunospecifically bind to a WNV antigen. The present invention also relates to detectable or diagnostic compositions comprising humanized antibodies or fragments thereof that immunospecifically bind to a WNV antigen and methods for detecting or diagnosing WNV infection utilizing said compositions.

Подробнее
Номер записи: 3
03-05-2012 дата публикации

Ex vivo animal or challenge model as method to measure protective immunity directed against parasites and vaccines shown to be protective in the method

Номер: US20120107342A1
Автор: Bernard Adri Bokhout, Florine Johanna Van Milligen, Johannes Bernardus Wilhelmus Joseph Cornelissen
Принадлежит: Stichting Dienst Landbouwkundig Onderzoek DLO

Described is an ex vivo animal or challenge model used as a method to identify protective (e.g., recombinant) proteins and rapidly measure protective immunity in intestinal segments directed against parasites and vaccines directed against parasitic infections. Further described are vaccines directed against infection with parasites, such as Fasciola hepatica , which vaccines contain protective (recombinant) proteins identified and shown to be protective in studies using the ex vivo model. Further described are protective (e.g., recombinant) proteins obtained from newly excysted juveniles (NEJ) of F. hepatica . The protective (recombinant) protein corresponding to an NEJ protein has an apparent molecular weight of 32 kD and an N-terminal amino acid molecule comprising the sequence XXDVSWPFWDRMYNY (SEQ ID NO:1).

Подробнее
Номер записи: 4
09-08-2012 дата публикации

Materials and methods for assay of anti-hepatitis c virus (hcv) antibodies

Номер: US20120202295A1
Автор: A. Scott Muerhoff, Dinesh Shah, George J. Dawson, Robin A. Gutierrez, Suresh M. Desai, Thomas P. Leary
Принадлежит: ABBOTT LABORATORIES

A polypeptide comprising the contiguous amino acids 1-198 of SEQ ID NO: 2; a polypeptide, which comprises a contiguous amino acid sequence that is at least about 95% identical to the contiguous amino acids 1-198 of SEQ ID NO: 2, an epitope that is immunoreactive with an antibody that specifically binds to the core protein of hepatitis C virus (HCV), and an epitope that is immunoreactive with an antibody that specifically binds to the NS4 region of HCV; a nucleic acid encoding such a polypeptide; a host cell comprising such a nucleic acid; an immunodiagnostic reagent comprising such a polypeptide; a kit comprising such an immunodiagnostic reagent; and a method of determining the presence, amount, or concentration of anti-HCV antibodies in a test sample.

Подробнее
Номер записи: 5
16-08-2012 дата публикации

Methods of assessing crohn's disease patient phenotype by i2, ompc and asca serologic response

Номер: US20120208212A1
Автор: Eric A. Vasiliauskas, Huiying Yang, Jerome I. Rotter, Phillip R. Fleshner, Stephan R. Targan, William S. Mow
Принадлежит: Cedars Sinai Medical Center

The invention provides a method of diagnosing or predicting susceptibility to a clinical subtype of Crohn's disease in a subject having Crohn's disease by determining the presence or absence of IgA anti-I2 antibodies in the subject, where the presence of the IgA anti-I2 antibodies indicates that the subject has a clinical subtype of Crohn's disease. In one embodiment, a method of the invention is practiced by further determining the presence or absence in the subject of a NOD2 variant, anti- Saccharomyces cerevisiae antibodies (ASCA), IgA anti-OmpC antibodies, or perinuclear anti-neutrophil cytoplasmic antibodies (pANCA). The methods of the invention can be used to diagnose or predict susceptibility to a clinical subtype of Crohn's disease, for example, a fibrostenotic subtype, a subtype characterized by the need for small bowel surgery, or a subtype characterized by the absence of features of ulcerative colitis.

Подробнее
Номер записи: 6
27-09-2012 дата публикации

Method for detecting microorganisms belonging to mycoplasma pneumoniae and/or mycoplasma genitalium

Номер: US20120244544A1
Автор: Atsuko Minagawa, Hatsue Itagaki, Kazuyuki Sugiyama, Toyomasa Hiroshima, Yasushi Shimada, Yuki Mitobe
Принадлежит: LSI Medience Corp

A detection method and a detection kit for rapidly and specifically diagnosing Mycoplasma pneumoniae and/or Mycoplasma genitalium infections are provided. The DnaK of Mycoplasma pneumoniae or Mycoplasma genitalium is used as an indicator.

Подробнее
Номер записи: 7
01-11-2012 дата публикации

Extracellular matrix proteins from haemophilus influenzae biofilms: targets for therapeutic or diagnostic use

Номер: US20120276145A1
Автор: James Kerwin, Paul Webster, Siva Wu
Принадлежит: HOUSE RES INST

A method of identifying a biofilm that includes non-typeable Haemophilus influenza (NTHi) including a step of screening a sample for the presence of one or more biofilm-specific proteins that are expressed by NTHi. In some cases, an NTHi biofilm-related disease in a subject is diagnosed. Also disclosed are protein microarrays for screening biofilm-specific proteins in a sample, formulations comprising one or more biofilm-specific proteins or fragments thereof, and methods for inducing an immune response in a patient against a biofilm-related infection.

Подробнее
Номер записи: 8
08-11-2012 дата публикации

Functional mutation in respiratory syncytial virus

Номер: US20120282673A1
Автор: Bin Lu, HONG Jin, Robert Brazas
Принадлежит: MEDIMMUNE LLC

The present invention provides recombinant respiratory syncytial viruses that have an attenuated phenotype and that comprise one or more mutations in the viral P, M2-1 and/or M2-2 proteins, as well as live attenuated vaccines comprising such viruses and nucleic acids encoding such viruses. Recombinant RSV P, M2-1 and M2-2 proteins are described. Methods of producing attenuated recombinant RSV, and methods of quantitating neutralizing antibodies that utilize recombinant viruses of family Paramyxoviridae, are also provided.

Подробнее
Номер записи: 9
20-12-2012 дата публикации

Group a streptococcus multivalent vaccine

Номер: US20120321657A1
Автор: James B. Dale
Принадлежит: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION

Immunogenic compositions are provided herein that are useful for inducing an immune response specific against group A streptococcus (GAS). Immunogenic compositions provided herein are multivalent and comprise a plurality of immunogenic peptides or fusion polypeptides comprising the immunogenic peptides that induce an immune response against GAS. The immunogenic compositions provided herein induce an immune response against the GAS serotypes represented by an immunogenic peptide (derived from an M protein or Spa protein) comprised within the immunogenic composition and also induce an immune response against serotypes that are unrepresented by any immunogenic peptide included in the immunogenic composition. Methods for using the compositions for inducing an immune response against GAS and for treating or reducing the likelihood of occurrence of a GAS infection are also provided.

Подробнее
Номер записи: 10
21-03-2013 дата публикации

Compositions And Methods For Immunodominant Antigens of Mycobacterium Tuberculosis

Номер: US20130072398A1
Автор: Maria Laura Gennaro, Philip Felgner, Xiaowu Liang
Принадлежит: IMMPORT THERAPEUTICS Inc, UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY

Contemplated compositions, devices, and methods are drawn to various antigens from the pathogen M. tuberculosis and their use in vaccines, therapeutic agents, and various diagnostic tests. In particularly preferred aspects, the antigens are immunodominant and have quantified and known relative reactivities with respect to sera of a population infected with the pathogen, and/or have a known association with a disease parameter.

Подробнее
Номер записи: 11
13-06-2013 дата публикации

Human Monoclonal Antibodies Against Hendra and Nipah Viruses

Номер: US20130149246A1
Автор: Christopher C. Broder, Dimiter S. Dimitrov, Zhongyu Zhu
Принадлежит: Henry M Jackson Foundation for Advancedment of Military Medicine Inc, US Department of Health and Human Services

The present invention relates to monoclonal antibodies that bind or neutralize Hendra or Nipah virus. The invention provides such antibodies, fragments of such antibodies retaining Hendra or Nipah virus-binding ability, fully human antibodies retaining Hendra or Nipah virus-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.

Подробнее
Номер записи: 12
27-06-2013 дата публикации

Compositions and methods for screening for lyme disease

Номер: US20130164759A1
Автор: Adriana Marques, Michael J. Iadarola, Peter D. Burbelo
Принадлежит: US Department of Health and Human Services, US Government

The invention provides compositions, methods, and kits for the diagnosis or detection of infection by a pathogen that causes Lyme disease in a subject.

Подробнее
Номер записи: 13
27-06-2013 дата публикации

Method and system for diagnosis of lawsonia intracellularis

Номер: US20130164765A1
Автор: Allen E. Page, David W. Horohov, Harold F. STILLS, JR.
Принадлежит: University of Kentucky Research Foundation

A method, system, and kit are provided for diagnosing L. intracellularis infection or exposure in a subject. The method includes purifying whole L. intracellularis from host cells and host debris produced in or on a suitable medium and adhering the purified whole L. intracellularis on a suitable material to form an antigen substrate for determining whether a subject produces L. intracellularis -specific antibodies against the antigen to thereby indicate L. intracellularis exposure or infection in the subject. The kit includes purified whole L. intracellularis produced from host cells and host debris adhered to a suitable material to form an antigen substrate adapted for screening serum from a subject. A method for diagnosing L. intracellularis exposure or infection in a subject includes acquiring a serum sample from a subject, introducing the serum sample to an antigen substrate followed by detecting a presence of L. intracellularis -specific antibodies in the serum.

Подробнее
Номер записи: 14
11-07-2013 дата публикации

Functional influenza virus-like particles (vlps)

Номер: US20130177587A1
Автор: Peter M. Pushko, Robin A. Robinson
Принадлежит: Novavax Inc

Recombinant influenza virus proteins, including influenza capsomers, subviral particles, virus-like particles (VLP), VLP complexes, and/or any portions of thereof, are provided as a vaccine for influenza viruses. The invention is based on the combination of two vaccine technologies: (1) intrinsically safe recombinant vaccine technology, and (2) highly immunogenic, self-assembled protein macromolecules embedded in plasma membranes and comprised of multiple copies of influenza virus structural proteins exhibiting neutralizing epitopes in native conformations. More specifically, this invention relates to the design and production of functional homotypic and heterotypic recombinant influenza virus-like particles (VLPs) comprised of recombinant structural proteins of human influenza virus type A/Sydney/5/94 (H3N2) and/or avian influenza virus type A/Hong Kong/1073/99 (H9N2) in baculovirus-infected insect cells and their application as a vaccine in the prevention of influenza infections and as a laboratory reagent for virus structural studies and clinical diagnostics.

Подробнее
Номер записи: 15
18-07-2013 дата публикации

Methods And Compositions For Detecting Fungi And Mycotoxins

Номер: US20130183697A1
Автор: Dennis G. Hooper
Принадлежит: Medical Service Consultation International LLC

The invention relates to a method of identifying a specific fungal species in patient tissue or body fluid. The method comprises the steps of extracting and recovering DNA of the fungal species from the patient tissue or body fluid, amplifying the DNA, hybridizing a probe to the DNA to specifically identify the fungal species, and specifically identifying the fungal species. The invention also relates to a method of identifying a mycotoxin in patient tissue or body fluid. The method comprises the steps of extracting and recovering the mycotoxin from the patient tissue or body fluid, contacting the mycotoxin with an antibody directed against the mycotoxin, and identifying the myocotoxin. Both of these methods can be used to determine if a patient is at risk for or has developed a disease state related to a fungal infection, and to develop an effective treatment regimen for the patient.

Подробнее
Номер записи: 16
15-08-2013 дата публикации

Immunogenic compositions comprising mycobacterium tuberculosis polypeptides and fusions thereof

Номер: US20130209500A1
Автор: Gregory C. Ireton, Rhea N. Coler, Steven G. Reed
Принадлежит: Infectious Disease Research Institute Inc

The present invention relates to compositions and fusion proteins containing at least two Mycobacterium sp. antigens, and polynucleotides encoding such compositions and fusion proteins. The invention also relates to methods for their use in the treatment, prevention and/or diagnosis of tuberculosis infections.

Подробнее
Номер записи: 17
15-08-2013 дата публикации

Borrelia Diagnostics and Screening Methods

Номер: US20130210651A1
Автор: Alan G. Barbour, Philip L. Felgner
Принадлежит: UNIVERSITY OF CALIFORNIA

The present invention provides methods of detecting Borrelia species in a sample (e.g., a sample from a patient suspected of being infected). In particular, the present invention provides compositions and methods for detecting the presence of Borrelia proteins, nucleic acid sequences encoding these proteins, and subject antibodies to these proteins, where the proteins are selected from those listed in Table 3, including: BB0279 (FLiL), BBK19, BBK07, BB0286 (FlbB), BBG33, BBL27, BBN34, BBP34, BBQ42, BBQ34, BBM34, BBN27, and BBH13.

Подробнее
Номер записи: 18
24-10-2013 дата публикации

Peptides protective against s. pneumoniae and compositions, methods and uses relating thereto

Номер: US20130280288A1
Автор: Alexander Von Gabain, Andreas Meinke, Astrid Teubenbacher, Beatrice Tschanun, Carmen Giefing-Krell, Eszter Nagy, Jutta Pikalo, Manuel Zerbs, Markus Hanner
Принадлежит: Valneva Austria GmbH

The present invention relates to a protective peptide of Streptococcus pneumoniae ( S. pneumoniae ) or a functionally active variant thereof; a composition comprising at least two of such peptides or variants; one or more nucleic acid(s) encoding such peptide or variant; a pharmaceutical composition comprising such peptide or variant, composition, or nucleic acid(s); a method of producing an antibody using such peptide or variant or composition; the use of such peptide or variant and/or composition and/or nucleic acid(s) for the manufacture of a medicament; a method of diagnosing a S. pneumoniae infection using such peptide or variant, composition or a primer and/or probe specific for the nucleic acid(s); a method for identifying a ligand capable of binding to such peptide or variant; and the use of such peptide or variant for the isolation, purification and/or identification of an interaction partner of the peptide.

Подробнее
Номер записи: 19
23-01-2014 дата публикации

Boone Cardiovirus

Номер: US20140024015A1
Автор: Judith D. Gohndrone, Lela Kay Riley, Matthew Howard Myles
Принадлежит: Idexx Laboratories Inc

The invention provides an isolated Boone cardiovirus, Boone cardiovirus polypeptides, polynucleotides and antibodies specific for Boone cardiovirus polypeptides. Also provided are methods for detection of Boone cardiovirus.

Подробнее
Номер записи: 20
27-03-2014 дата публикации

Oxidized cardiolipin and uses to detect cardiolipin antibodies

Номер: US20140087398A1
Автор: Arnold R. Castro, Himanshu Champaklal Mody
Принадлежит: Arlington Scientific Inc, US Department of Health and Human Services

Compositions, methods and devices for the detection of anti-lipoidal antibodies and the diagnosis of disease, for example, syphilis, are described. In particular, oxidized cardiolipins, which may be conjugated with a variety of attachment molecules, such as BSA, KLH, biotin, synthetic protein MAPS, IgY, streptavidin, or avidin, are described. Such oxidized cardiolipin, alone or complexed with one or more attachment molecules, are useful to detect anti-lipoidal antibodies (such as IgG and IgM antibodies) in subjects, for example, when used in ELISA plates. ELISA plates are described that permit the detection of anti-lipoidal antibodies and that permit the co-detection of nontreponemal and treponemal antibodies in biological samples.

Подробнее
Номер записи: 21
07-01-2016 дата публикации

RECOMBINANT ANTIGENS OF PORCINE CIRCOVIRUS 2 (PCV-2) FOR VACCINE FORMULATIONS, DIAGNOSTIC KIT AND USE THEREOF

Номер: US20160000897A1
Автор: AMAZILES SILVA LEITE Roberta, ANDRADE TEIXEIRA Jackson de, BRESSAN Gustavo Costa, CRISPIM Josicelli Souza, DE ALMEIDA Márcia Rogéria, DE CRUZ SOUZA Amanda Martins, DE MORAIS MONTEIRO Antônio, FAUSTO Mariana Costa, FIALHO GONZAGA Natália, FIETTO Juliana Lopes Rangel, JAQUEL ZILCH Tiago, JUNIOR Abelardo Silva, KALKS Sthefany Patareli, LINO DE SOUZA Luiz Fernando, ONOFRE Thiago Souza, SALGADO Rafael Locatelli, VIDIGAL Pedro Marcus Pereira
Принадлежит:

The present invention relates to the preparation of the recombinant antigen of the viral capsid of 2 (PCV-2) and modifications thereof, upon expression in a prokaryotic system, purification in the monomer form, recovery of virus-like particles (VLPs) and their use in vaccine formulations, diagnostic kits and a system for quantifying in vaccine lots of the PCV-2 antigen by means of a capture ELISA assay. The antigens and vaccine formulations can be used in animal's immunization in programs for combatting PCV-2-associated diseases in conventional swine breeding systems, and represent alternatives to the commercially available vaccines. The ELISA kit can be used for testing the quality of commercial and/or experimental vaccines against PCV-2. 1porcine circovirus. Recombinant antigen of the 2 which is the SEQ ID NO: 02.2. Recombinant antigen according to claim 1 , which comprises 10 histidine residues positioned at amino terminal region of the capsid recombinant protein of the PCV-2.3. Recombinant antigen claim 1 , according to claim 1 , which comprises the product of the oligomerization of the SEQ ID NO: 02 as virus-like particles (VLPs) of the PCV-2.4. Vaccine Formulations claim 1 , which comprise the recovered antigen as defined in claim 1 , associated with pharmaceutically acceptable adjuvants.5. Capture Elisa type diagnostic kit which comprises the SEQ ID NO: 02 as defined in claim 1 , and anti-SEQ ID: 02 antibodies.6. Uses of the antigens as defined in claim 1 , which is applied in the production of diagnostic kits and the production of vaccine compounds.7. Use of the vaccine formulations defined in claim 4 , which is for the control of diseases related to the PCV-2.8. Use of the diagnostic kit as defined in claim 5 , which is for capsid protein quantification of the PCV-2 claim 5 , more specifically in quality control vaccine formulations.9. Recovery Process of the antigens and virus-like particles of claim 1 , which comprises the following steps:{'sub': 4', '2', ...

Подробнее
Номер записи: 22
05-01-2017 дата публикации

Method for the vaccination against hiv

Номер: US20170000876A1
Автор: Anker LUNDEMOSE, Arnt Ove HOVDEN, Maja Sommerfelt GRØNVOLD, Mats Okvist
Принадлежит: Bionor Immuno AS

The present invention relates to novel compositions of active agents and methods for the treatment of HIV infection and AIDS. In particular, the present invention relates to novel methods to select HIV infected patients with improved responses to HIV-specific vaccine peptides.

Подробнее
Номер записи: 23
04-01-2018 дата публикации

COMPOSITIONS CONTAINING COMBINATIONS OF BIOACTIVE MOLECULES DERIVED FROM MICROBIOTA FOR TREATMENT OF DISEASE

Номер: US20180000921A1
Автор: Atarashi Koji, Fukuda Shinji, Hase Koji, Honda Kenya, Ohno Hiroshi, Olle Bernat, Tanoue Takeshi
Принадлежит:

Compositions consisting of bioactive molecules derived from the microbiota of a mammal are provided herein. When administered orally with a colonic delivery system, the compositions are useful for the prophylaxis and treatment of diseases, in particular inflammatory, autoimmune and infectious diseases. The compositions comprise combinations of small molecules and bacterial antigens formulated in colonic delivery systems. Use of the compositions results in any or all of: induction of immune tolerance; strengthening of the gut mucosal barrier integrity; reduction of inflammation; and amelioration of a disease state caused by inflammation, an autoimmune reaction or an infectious agent. 1. A composition that induces proliferation and/or accumulation of regulatory T cells , the composition comprising: (a) and (b) , or (a) and (c) ,wherein (a) is one or more short-chain fatty acids or short-chain fatty acid derivative;{'i': Clostridium', 'Clostridium', 'Clostridium, 'wherein (b) is one or more antigens derived from bacteria belonging to Cluster IV, Cluster XIVa, or Cluster XVIII; and,'}wherein (c) is a flagellin polypeptide.2. The composition of claim 1 , wherein (a) is selected from the group consisting of butyrate claim 1 , isobutyrate claim 1 , proprionate claim 1 , acetate claim 1 , tributyrin claim 1 , pivaloyloxymethyl butyrate claim 1 , and monoacetone glucose 3-butyrate.3. The composition of claim 1 , wherein (a) is butyrate.4. The composition of claim 1 , wherein (a) is a mixture of salts of butyrate claim 1 , isobutyrate claim 1 , propionate claim 1 , and acetate.5. The composition of claim 1 , wherein (c) is selected from the group consisting of flagellin claim 1 , a flagellin component claim 1 , CBir1 claim 1 , Fla-X claim 1 , FIiC claim 1 , FliD claim 1 , FlgK claim 1 , FlgC and FlgE.6. The composition of claim 1 , wherein (c) is flagellin.7ClostridiumClostridiumClostridiumClostridiumClostridiumClostridiumClostridiumClostridiumClostridium. The composition of ...

Подробнее
Номер записи: 24
04-01-2018 дата публикации

CIRCOVIRUS SEQUENCES ASSOCIATED WITH PIGLET WEIGHT LOSS DISEASE (PWD)

Номер: US20180000927A1
Автор: ALBINA EMMANUEL, ARNAULD CLAIRE, BLANCHARD PHILIPPE, CARIOLET ROLAND, HUTET EVELYNE, JESTIN ANDRÉ, LE CANN PIERRE, MADEC FRANÇOIS, MAHE DOMINIQUE, TRUONG CATHERINE
Принадлежит: Zoetis Services LLC

The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus, also are provided. Method for selecting compounds capable of modulating the viral infection are further provided. Pharmaceutical, including vaccine, compositions for preventing and/or treating viral infections caused by PWD circovirus and the use of vectors for preventing and/or treating diseases also are provided. 114.-. (canceled)15. A vaccine for protecting a pig against infection by a piglet weight loss disease circovirus comprising: an isolated ORF′2 polypeptide of porcine circovirus Type B (PCVB); and a recombinant expression vector.16. The vaccine of claim 15 , wherein the recombinant expression vector is a baculovirus expression vector.17. The vaccine of claim 15 , further comprising an adjuvant.18. The vaccine of claim 15 , further comprising a pharmaceutically or veterinarily acceptable carrier.19. The vaccine of claim 15 , wherein the ORF′2 polypeptide has at least 90% identity to the sequence of SEQ ID NO:26.20. The vaccine of claim 15 , wherein the ORF′2 polypeptide has at least 95% identity to the sequence of SEQ ID NO:26.21. The vaccine of claim 15 , wherein the ORF′2 polypeptide is encoded by a nucleic acid having at least 90% identity to the sequence of SEQ ID NO:25.22. A method for protecting a pig against infection by a piglet weight loss disease circovirus comprising: administering to the pig the vaccine of .23. The method of claim 22 , wherein the vaccine is administered to a pig 3 weeks of age or older.24. The method of claim 22 , wherein the vaccine is administered as a single dose.25. The method of claim 22 , wherein the vaccine is administered via a route selected from the group ...

Подробнее
Номер записи: 25
06-01-2022 дата публикации

High-affinity human ace2 construct for use in diagnosing and treating coronaviruses

Номер: US20220002701A1
Автор: Bing Chen, Jun Zhang, Tianshu XIAO, Yongfei Cai
Принадлежит: Childrens Medical Center Corp

Provided herein, in some aspects, are polypeptide monomers comprising an angiotensin-converting enzyme 2 (ACE2) ectodomain and an oligomerization domain. Also provided herein are oligomeric complexes comprising ACE2 monomers. Methods of using such to monomers and oligomeric complexes for the diagnosis, prevention, and treatment of viral infections such as the coronavirus are also provided.

Подробнее
Номер записи: 26
07-01-2016 дата публикации

IDIOTYPIC ANTIBODIES AND USES THEREOF

Номер: US20160002355A1
Автор: Hongo Jo-Anne, Li Yanhong, Liu Luna, Lowe John, Maia Mauricio, Vij Rajesh, Wong Terence, XU Keyang
Принадлежит:

The invention provides anti-idiotypic HCMV antibodies as well as methods of using the same. 1. An isolated anti-idiotypic antibody that specifically binds to an anti-HCMV antibody comprising the heavy chain sequence of SEQ ID NO: 3 and the light chain sequence of SEQ ID NO: 4.25-. (canceled)6. The anti-idiotypic antibody of claim 1 , wherein the anti-idiotypic antibody comprises three heavy chain hypervariable regions (HVR-H1 claim 1 , HVR-H2 and HVR-H3) and three light chain hypervariable regions (HVR-L1 claim 1 , HVR-L2 and HVR-L3) claim 1 , wherein:(a) HVR-H1 comprises the amino acid sequence of SEQ ID NO: 19;(b) HVR-H2 comprises the amino acid sequence of SEQ ID NO: 20;(c) HVR-H3 comprises the amino acid sequence of SEQ ID NO: 21;(d) HVR-L1 comprises the amino acid sequence of SEQ ID NO: 22;(e) HVR-L2 comprises the amino acid sequence of SEQ ID NO: 23; and(f) HVR-L3 comprises the amino acid sequence of SEQ ID NO: 24.7. The anti-idiotypic antibody of claim 6 , wherein the anti-idiotypic antibody comprises the heavy chain sequence of SEQ ID NO: 9 and the light chain sequence of SEQ ID NO: 11.8. (canceled)9. The anti-idiotypic antibody of claim 1 , wherein the anti-idiotypic antibody specifically binds to at least one HVR of an anti-HCMV antibody comprising the heavy chain sequence of SEQ ID NO: 3 and the light chain sequence of SEQ ID NO: 4.10. The anti-idiotypic antibody of claim 1 , wherein the anti-idiotypic antibody specifically binds to HVR-H2 (SEQ ID NO: 36) of an anti-HCMV antibody comprising the heavy chain sequence of SEQ ID NO: 3 and the light chain sequence of SEQ ID NO: 4.11. The anti-idiotypic antibody of conjugated to a detectable label.12. The antibody of conjugated to biotin.1343-. (canceled)44. An immunoassay kit for specifically detecting in a biological sample an antibody of interest selected from (a) a first anti-HCMV antibody comprising the heavy chain sequence of SEQ ID NO: 3 and a light chain sequence of SEQ ID NO: 4; and (c) a combination ...

Подробнее
Номер записи: 27
04-01-2018 дата публикации

IMMUNOLOGICAL DETECTION METHOD AND KIT FOR MYCOPLASMA PNEUMONIAE

Номер: US20180002407A1
Автор: Saito Kenji
Принадлежит: TAUNS CO., LTD.

The present invention aims at providing a specific antibody that can simply and rapidly detect which is a causative bacterium of , with high sensitivity, and also an immunological detection method and a kit containing the same antibody. The present invention makes it possible to diagnose infection with more rapidly and specifically than the conventional method, by producing an antibody recognizing a specific epitope of P30 protein of and performing an immunological detection using the antibody. Also, the present invention enables easy and rapid detection of and diagnosis of infection with the same at a hospital or the like without need of specialized instruments or skilled techniques. 1Mycoplasma pneumoniaeMycoplasma pneumoniae. A method of detecting , comprising an immunoassay using an antibody against P30 protein of , the antibody being an antibody against an epitope of P30 protein located in an amino acid sequence of SEQ ID NO: 3 or 4.2. The detecting method according to claim 1 , wherein the antibody is a monoclonal antibody.3Mycoplasma pneumoniaeMycoplasma pneumoniae. A method of detecting claim 1 , comprising a sandwich immunoassay using first and second antibodies against P30 protein of claim 1 , wherein at least one of the first and second antibodies is an antibody against an epitope of P30 protein located in an amino acid sequence of SEQ ID NO: 3 or 4.4. The detecting method according to claim 3 , wherein the sandwich immunoassay is an ELISA or immunochromatographic assay.5. The detecting method according to claim 3 , wherein at least one of the first and second antibodies is a monoclonal antibody.6. The detecting method according to claim 5 , wherein one of the first and second antibodies is immobilized in a carrier.7Mycoplasma pneumoniae. An immunochromatographic assay for detecting claim 5 , comprising:{'i': 'Mycoplasma pneumoniae', 'providing a membrane carrier having a capturing zone that is formed by previously immobilizing a first antibody against ...

Подробнее
Номер записи: 28
05-01-2017 дата публикации

RAPID DUAL DIRECT FLUORESCENT ASSAY FOR THE IDENTIFICATION OF BACILLUS ANTRHACIS

Номер: US20170003287A1
Автор: Abshire Teresa G, Ribot Wilson J
Принадлежит:

In this application is described a method for rapidly and accurately identifying in a sample by simultaneously detecting the presence of cell wall antigen and capsule antigen in the same sample culture grown under capsule inducing conditions. Other uses and advantages of the method of the invention are described herein. 1B. anthracis. A method for detecting the presence of in a sample , said method comprising(i) culturing said sample under capsule inducing conditions thereby producing a cultured sample;contacting said cultured sample simultaneously with two antibodies, antibody one and Fab antibody two, each detectably labeled with a different identifiable signal moiety whereinantibody one specifically binds to a capsule antigenFab antibody two specifically binds to a cell wall antigen; and{'i': 'B. anthracis', 'detecting the presence of the detectable signal from antibody one and antibody two wherein presence of detectable signal from both antibodies indicates presence of in said sample.'}2B. anthracis. The method of claim 1 , wherein antibody one specifically binds to capsule poly-D-glutamic acid.3. The method of wherein antibody one is mAb FDF-1B9.4B. anthracis. The method of wherein Fab antibody two specifically binds to cell wall galactose-N-acetyl-glucosamine.5. The method of wherein said Fab antibody two is mAb EAII-6G6Fab.6. The method of wherein Fab antibody two is mAb EAII-6G6 Fab.7. The method of wherein antibody one and Fab antibody two are labeled with a contrasting fluorophore.8. The method of wherein the fluorophore is fluorescein isothiocyanate claim 7 , rhodamine claim 7 , luciferin claim 7 , auramine claim 7 , Texas red claim 7 , or AMCA blue.9. The method of wherein the sample is a biological claim 1 , environmental claim 1 , or forensic sample.10. The method of wherein said biological sample from a subject wherein said sample is cells claim 9 , blood claim 9 , tissues claim 9 , or biological fluid.11. The method of wherein said subject is human ...

Подробнее
Номер записи: 29
05-01-2017 дата публикации

HCV ANTIGEN-ANTIBODY COMBINATION ASSAY AND METHODS AND COMPOSITIONS FOR USE THEREIN

Номер: US20170003290A9
Автор: Bogdan M. Felicia, DAWSON GEORGE J., Desai Suresh M., Gutierrez Robin A., Marohnic Christopher C., Muerhoff A. Scott, Prostko John
Принадлежит:

The present invention generally relates to combination immunoassays, reagents and kits for simultaneous detection of HCV antigens and anti-HCV antibodies in a test sample. 120-. (canceled)21. An immunoassay for the combined detection of HCV antigen and HCV antibody in a test sample comprising: i) a solid phase comprising a tag binding partner,', 'ii) a test sample,', 'iii) an anti-HCV core monoclonal antibody for the capture of an HCV core antigen present said test sample, wherein said anti-HCV core monoclonal antibody comprises a first tag;', 'iv) a first HCV capture antigen for the capture of anti-HCV antibody in said test sample, wherein said first HCV capture antigen comprises: A) at least a portion of a mutant HCV core protein that is not detectably recognized by said anti-HCV core monoclonal antibody, and B) a second tag; and', 'v) a detectably labeled first HCV detection antigen for binding to said anti-HCV antibody captured by said first HCV capture antigen; and, 'a) providing the following components (i) said anti-HCV core monoclonal antibody binds to said solid phase through said first tag and specifically binds to HCV core antigen present in said test sample to produce an anti-HCV core monoclonal antibody-HCV antigen complex captured on said solid phase; and', '(ii) said first HCV capture antigen binds to said solid phase through said second tag and specifically binds to anti-HCV core antibodies present in said test sample to produce a first HCV capture antigen-anti-HCV antibody complex captured on said solid phase, and said detectably labeled first HCV detection antigen specifically binds to the anti-HCV antibody in said first HCV capture antigen-anti-HCV antibody complex captured on said solid phase;, 'b) incubating the components of step (a) under conditions to produce a reaction mixture such thatc) isolating said solid phase;d) contacting the isolated solid phase with a detectably labeled conjugate antibody that binds to said HCV antigen captured in ...

Подробнее
Номер записи: 30
07-01-2021 дата публикации

Dual channel immuno-quantitative test strip of Zearalenone-Deoxynivalenol

Номер: US20210003565A1
Автор: JI Jian, Li Miao, Liu Ying, SUN Jiadi, SUN Xiulan, ZHANG Yinzhi
Принадлежит:

The disclosure relates to a zearalenone-deoxynivalenol dual-channel immunoquantitative test strip and belongs to the technical field of immunoassay rapid detection. The disclosure prepares fluorescent probes by labeling with fluorescent microspheres, including a fluorescent microsphere-zearalenone monoclonal antibody, a fluorescent microsphere-deoxynivalenol monoclonal antibody and a fluorescent microsphere-goat anti-mouse second antibody. A zearalenone artificial antigen, a fluorescent microsphere artificial antigen and a goat anti-mouse second antibody are respectively sprayed on a nitrocellulose membrane to serve as a detection line T1, a detection line T2 and a quality control line C to prepare the immunochromatographic test strip; a competitive immunoassay method is adopted, and zearalenone and deoxynivalenol in samples are quantitatively analyzed at the same time by reading fluorescence values of the detection lines on a fluorescence immunoanalyzer. This method for preparing fluorescent probes not only overcomes the shortcoming of difficult storage of colloidal gold in the test strip technology, but also is simple, efficient and high in sensitivity. 1. A zearalenone-deoxynivalenol dual-channel immunoquantitative test strip , comprising a sample pad , a nitrocellulose membrane and absorbent paper , wherein the nitrocellulose membrane comprises a zearalenone artificial antigen , a vomitoxin artificial antigen and a goat anti-mouse second antibody to be used as a detection line T1 , a detection line T2 and a quality control line C , respectively , wherein the zearalenone artificial antigen is 0.2-1.6 μg/cm , and the deoxynivalenol artificial antigen is 0.1-1.2 μg/cm.2. The test strip according to claim 1 , wherein a distance between the three lines of the detection line T1 claim 1 , the detection line T2 and the quality control line C is 0.3-0.5 cm.3. The test strip according to claim 1 , wherein the absorbent paper claim 1 , the nitrocellulose membrane and the ...

Подробнее
Номер записи: 31
13-01-2022 дата публикации

METHOD OF ASSESSING RISK OF PML

Номер: US20220011310A1
Автор: Bloomgren Gary Lewis, Bozic Carmen, Lee Sophia, Plavina Tatiana, Subramanyam Meena
Принадлежит:

The invention relates to methods of assessing a patient's risk of developing Progressive multifocal leukoencephalopathy (PML). 185.-. (canceled)86. A method of treating a Multiple Sclerosis (MS) patient , the method comprising acquiring the result of an assay for detecting JC Virus (JCV) antibodies in a biological sample from the patient , and responsive to a determination that the sample is negative for anti-JCV antibodies , administering an anti-VLA-4 therapy , wherein the assay comprises:a) forming a first reaction mixture comprising a first aliquot of said sample and a substrate on which is disposed highly purified viral-like particles (HPVLP);b) detecting the level of anti-JCV antibody bound to said substrate on which is disposed HPVLP by detecting a labeled detection reagent bound to anti-JCV antibody bound to said substrate, evaluating a cut-off calibrator having a score of about 1, a positive control having a score of about 1.3, and a negative control having a score of about 0.1, and assigning to the sample a value indicative of the level of anti-JCV antibody;c) responsive to a level of anti-JCV antibody corresponding to a nOD value between 0.2 and 0.4 in step b), forming a second reaction mixture containing a second aliquot of said sample and solution-phase HPVLP, and detecting the level of unbound antibody in said second reaction mixture, by detecting anti-JCV antibody capable of binding with a substrate on which is disposed HPVLP;d) forming a third reaction mixture containing a third aliquot under conditions where anti-JCV antibodies in the sample are not bound by HPVLP or other antigen, and detecting the level of unbound anti-JCV antibody in the third reaction mixture by detecting anti-JCV antibody capable of binding with a substrate on which is disposed HPVLP; ande) determining the level to which the presence of HPVLP in the second reaction mixture inhibits the level of unbound anti-JCV antibody in said second reaction as compared with the level of ...

Подробнее
Номер записи: 32
08-01-2015 дата публикации

METHOD FOR DETECTING POLYOMAVIRUS REACTIVATION

Номер: US20150010901A1
Автор: Khalili Kamel, Sariyer Ilker K.
Принадлежит: TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION

The invention provides methods of detection and monitoring of polyomavirus reactivation and active polyomavirus infections using a biological fluid sample. Also provided are methods of risk assessment and risk monitoring of developing a polyomavirus-associated disease. 1. A method for detection of polyomavirus reactivation in a patient having or suspected of having a latent polyomavirus infection , the method comprising determining the presence or absence of a polyomavirus agnoprotein and/or the presence or absence of agnoprotein antibodies in the biological sample , wherein the biological sample is a body fluid , and wherein the presence of the polyomavirus agnoprotein or agnoprotein antibodies is indicative of reactivation of the polyomavirus in the patient.2. The method of claim 1 , wherein the polyomavirus is a mammalian polyomavirus claim 1 , a primate polyomavirus or a human polyomavirus.3. The method of claim 2 , wherein the polyomavirus is a human polyomavirus.4. The method of claim 3 , wherein the human polyomavirus is JC virus or BK virus.5. The method of claim 1 , wherein the biological sample is a body fluid selected from the group consisting of blood claim 1 , blood serum claim 1 , blood plasma claim 1 , urine claim 1 , and cerebrospinal fluid.6. The method of claim 1 , further comprising: 'comparing the level of the polyomavirus agnoprotein or agnoprotein antibodies in the biological sample to the level of polyomavirus agnoprotein or agnoprotein antibodies in a control sample,', 'measuring the level of the polyomavirus agnoprotein in the biological sample, and'}wherein an elevated level of the polyomavirus agnoprotein or agnoprotein antibodies in the biological sample relative to the level of polyomavirus agnoprotein or agnoprotein antibodies in the control sample is indicative of reactivation of the polyomavirus in the patient.7. The method of claim 6 , wherein the control sample is a positive control sample claim 6 , andwherein a level of the ...

Подробнее
Номер записи: 33
08-01-2015 дата публикации

Eukaryotic Cells with Artificial Endosymbionts for Multimodal Detection

Номер: US20150010937A1
Автор: Bazarov Alexey, Bell, III Caleb B.
Принадлежит:

The present invention is directed generally to eukaryotic cells comprising single-celled organisms that are introduced into the eukaryotic cell through human intervention and which transfer to daughter cells of the eukaryotic cell, and methods of introducing such single-celled organisms into eukaryotic cells. The invention provides single-celled organisms that introduce a phenotype to eukaryotic cells that is maintained in daughter cells. The invention additionally provides eukaryotic cells containing magnetic bacteria. The invention further provides eukaryotic cells engineered with single-celled organisms to allow for multimodal observation of the eukaryotic cells. Each imaging method (or modality) allows the visualization of different aspects of anatomy and physiology, and combining these allows the imager to learn more about the subject being imaged. 1. A multimodal probe comprising a magnetotactic bacterial cell , wherein the bacterial cell expresses one or more heterologous reporters selected from: a Positron Emission Tomography (PET) reporter , a Single Photon Emission Computed Tomography (SPECT) reporter , an X-Ray reporter , a photoacoustic reporter , and an ultrasound reporter.2. The multimodal probe of claim 1 , further expressing a fluorescent reporter.3. The multimodal probe of claim 1 , further expressing a bioluminescent reporter.4. The multimodal probe of claim 1 , wherein at least one reporter is a PET reporter.5. The multimodal probe of claim 1 , wherein at least one reporter is a SPECT reporter.6. The multimodal probe of claim 1 , wherein at least one reporter is an X-ray reporter.7. The multimodal probe of claim 1 , wherein at least one reporter is a photoacoustic reporter.8. The multimodal probe of claim 1 , wherein at least one reporter is an ultrasound reporter.9. The multimodal probe of claim 1 , wherein a reporter gene encoding the reporter is integrated into the genome of the bacterial cell.10. A eukaryotic cell comprising membrane-enclosed ...

Подробнее
Номер записи: 34
14-01-2016 дата публикации

MONOCLONAL ANTIBODIES THAT NEUTRALIZE A NOROVIRUS

Номер: US20160009788A1
Автор: Bok Karin, CHEN Zhaochun, Green Lisbeth Kim, PURCELL Robert H., Sosnovtsev Stanislav
Принадлежит: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human

Monoclonal neutralizing antibodies are disclosed that specifically bind to a Norovirus. In some embodiments, the Norovirus is a genogroup II Norovirus or a Genogroup II Norovirus. In some embodiments, the Norovirus is Norwalk virus. In some embodiments, the monoclonal antibodies specifically bind VP1. Also disclosed are compositions including the disclosed antibodies, nucleic acids encoding these antibodies, expression vectors including the nucleic acids, and isolated host cells that express the nucleic acids. The antibodies and compositions disclosed herein can be used for detecting the presence of a Norovirus in a biological sample, or detecting a Norovirus infection. In addition, the neutralization ability of the disclosed antibodies makes them ideal for treating a subject with a Norovirus infection. Thus, disclosed are methods of treating and/or preventing these infections. 2. (canceled)3. The isolated monoclonal antibody of claim 1 , wherein the heavy chain variable domain comprises the amino acid sequence set forth as one of SEQ ID NO: 8 claim 1 , SEQ ID NO: 24 claim 1 , SEQ ID NO: 40 claim 1 , SEQ ID NO: 56 claim 1 , SEQ ID NO: 72 claim 1 , SEQ ID NO: 88 claim 1 , SEQ ID NO: 104 claim 1 , SEQ ID NO: 120 claim 1 , or SEQ ID NO: 136.4. The isolated monoclonal antibody of claim 1 , wherein the light chain variable domain comprises the amino acid sequence set forth as SEQ ID NO: 16 claim 1 , SEQ ID NO: 32 claim 1 , SEQ ID NO: 48 claim 1 , SEQ ID NO: 64 claim 1 , SEQ ID NO: 80 claim 1 , SEQ ID NO: 96 claim 1 , SEQ ID NO: 112 claim 1 , SEQ ID NO: 128 or SEQ NO: 144.5. (canceled)6. The isolated monoclonal antibody of claim 1 , wherein:(a) the heavy chain variable domain comprises the amino acid sequence set forth as SEQ ID NO: 8 and the light chain variable domain comprises the amino acid sequence set forth as SEQ ID NO: 16;(b) the heavy chain variable domain comprises the amino acid sequence set forth as SEQ ID NO: 24 and the light chain variable domain comprises ...

Подробнее
Номер записи: 35
11-01-2018 дата публикации

IMMUNOLOGICAL DETECTION METHOD AND KIT FOR MYCOPLASMA PNEUMONIAE

Номер: US20180009880A1
Автор: Saito Kenji
Принадлежит: TAUNS CO., LTD.

The present invention aims at providing a specific antibody that can simply and rapidly detect which is a causative bacterium of pneumonia, with high sensitivity, and also an immunological detection method and a kit containing the same antibody. The present invention makes it possible to diagnose infection with more rapidly and specifically than the conventional method, by producing an antibody recognizing a specific epitope of P30 protein of and performing an immunological detection using the antibody. Also, the present invention enables easy and rapid detection of and diagnosis of infection with the same at a hospital or the like without need of specialized instruments or skilled techniques. 1Mycoplasma pneumoniae,Mycoplasma pneumoniae,. A method of detecting comprising an immunoassay using an antibody against P30 protein of the antibody being an antibody against an epitope of P30 protein located in any one of amino acid sequences of SEQ ID NOS: 3 to 5.2. The detecting method according to claim 1 , wherein the antibody is a monoclonal antibody.3Mycoplasma pneumoniae,Mycoplasma pneumoniae,. A method of detecting comprising a sandwich immunoassay using first and second antibodies against P30 protein of wherein at least one of the first and second antibodies is an antibody against an epitope of P30 protein located in any one of amino acid sequences of SEQ ID NOS: 3 to 5.4. The detecting method according to claim 3 , wherein the sandwich immunoassay is an ELISA or immunochromatographic assay.5. The detecting method according to claim 3 , wherein at least one of the first and second antibodies is a monoclonal antibody.6. The detecting method according to claim 5 , wherein one of the first and second antibodies is immobilized in a carrier.7Mycoplasma pneumoniae,. An immunochromatographic assay for detecting comprising:{'i': 'Mycoplasma pneumoniae', 'providing a membrane carrier having a capturing zone that is formed by previously immobilizing a first antibody against ...

Подробнее
Номер записи: 36
14-01-2016 дата публикации

Method for Diagnosing a Viral Infection

Номер: US20160011193A1
Автор: Gallerano Daniela, Sibanda Elopy N., Valenta Rudolf
Принадлежит:

The present invention relates to a method for detecting and/or quantifying human immunodeficiency virus (HIV) specific antibodies in a sample of a subject comprising the step of determining the presence and/or amount of antibodies binding to a) a peptide consisting of the amino acid sequence AIVCTRPNNNTRKSIRIGPGQVFYT (SEQ ID No. 1), or b) a homolog having at least 70% identity with a peptide of a), or c) a fragment of a peptide of a) or b) consisting of 15 to 24 amino acid residues in said sample. 1. A method for detecting or quantifying human immunodeficiency virus (HIV) specific antibodies in a sample of a subject comprising the step of determining the presence or amount of antibodies binding toa) a peptide consisting of the amino acid sequence AIVCTRP-NNNTRKS IRIGPGQVFYT (SEQ ID No. 1), orb) a homolog having at least 70% identity with a peptide of a), orc) a fragment of a peptide of a) or b) consisting of 15 to 24 amino acid residues,in said sample.2. (canceled)3. (canceled)4. (canceled)5. The method according to claim 1 , wherein further the presence or amount of antibodies binding toa) a peptide consisting of the amino acid sequence LLGLWGCSGKLICTTAVHWNSSWSN (SEQ ID No. 2), orb) a homolog having at least 70% identity with a peptide of a), orc) a fragment of a peptide of a) or b) consisting of 15 to 24 amino acid residues,in a sample of the subject is determined.6. The method according to claim 1 , wherein further the presence or amount of antibodies binding toa) a peptide consisting of the amino acid sequence NALFYRSDIVPLEKNSSEYILINCN (SEQ ID No. 3), orb) a homolog having at least 70% identity with a peptide of a), orc) a fragment of a peptide of a) or b) consisting of 15 to 24 amino acid residues,in a sample of the individual is determined.7. The method according to claim 1 , wherein further the presence or amount of antibodies binding toa) a peptide consisting of the amino acid sequence GIKQLQARVLAIERYLKDQQLLGLW (SEQ ID No. 4), orb) a homolog having at least ...

Подробнее
Номер записи: 37
09-01-2020 дата публикации

Human monoclonal antibodies to staphylococcus aureus lukab toxin

Номер: US20200010536A1
Автор: Buddy CREECH, Gopal SAPPARAPU, Isaac THOMSEN, James E. Crowe, Jr.
Принадлежит: VANDERBILT UNIVERSITY

The present disclosure is directed to antibodies binding to prefusion and postfusion forms of both human S. aureus and human metapneumovirus F proteins, including neutralizing antibodies, and methods for use thereof.

Подробнее
Номер записи: 38
11-01-2018 дата публикации

EVALUATING BIOLOGICAL MATERIAL FOR UNASSOCIATED VIRUS-LIKE PARTICLES

Номер: US20180010999A1
Автор: Artinger Michael A., Gates Tyler Donald, Kohlmeier Francis Kevin, Olszowy Michael W.
Принадлежит:

A method for evaluating a biological material for unassociated virus-like particles virus size having a particular epitope uses a fluorescent antibody stain specific for binding with the epitope and a fluid sample with the virus-size particles and fluorescent antibody stain is subjected to flow cytometry with identification of fluorescent emission detection events indicative of passage through a flow cell of a flow cytometer of unassociated labeled particles of virus size including such a virus-like particle and fluorescent antibody stain. 2. A method according to claim 1 , wherein the epitope is selected from the group consisting of a baculovirus epitope claim 1 , an adenovirus epitope claim 1 , an influenza virus epitope claim 1 , an enterovirus epitope claim 1 , an adeno-associated virus (AAV) epitope and a norovirus epitope.3. A method according to claim 1 , wherein the epitope is a first epitope claim 1 , the flow cytometry is first flow cytometry claim 1 , the fluid sample is a first fluid sample including a first portion of the of the biological material sample claim 1 , the unassociated labeled particles are first unassociated labeled particles and the excitation radiation is first excitation radiation claim 1 , and the method comprises: flowing the second fluid sample through a flow cell of a flow cytometer;', 'subjecting the second fluid sample flowing through the flow cell to second excitation radiation, which is the same as or different than the first excitation radiation, capable of causing a second fluorescent emission response that is different than the first fluorescent emission response from the second fluorescent antibody stain; and', 'detecting radiation from the flow cell within a wavelength range of the fluorescent emission and evaluating the detected radiation to identify detection events indicative of passage through the flow cell of second unassociated labeled particles of virus size including a particle of virus size having the second ...

Подробнее
Номер записи: 39
11-01-2018 дата публикации

HCV NS4A/MODIFIED NS3 POLYPEPTIDES AND USES THEREOF

Номер: US20180011096A1
Автор: CHIEN David Y., COIT Doris Guenzi, FUJIHARA Toshiya, GYENES Alexander, HALL John Andrew, MEDINA-SELBY Angelica, Zheng Jian
Принадлежит:

Modified hepatitis C virus polypeptides are described. The polypeptides include the HCV NS4a domain and modified NS3 domain. The polypeptides retain conformational epitopes. HCV immunoassays including the polypeptides are also described. 1. An immunoassay reagent comprising a polypeptide , the polypeptide comprising: a hepatitis C virus NS4a domain having SEQ ID NO:3; a modified hepatitis C virus NS3 domain having SEQ ID NO:4 , wherein one or more amino acid residues of SEQ ID NO:4 are modified such that protease activity of the modified hepatitis C virus NS3 domain is inhibited relative to protease activity of the hepatitis C virus NS3 domain having SEQ ID NO:4 lacking the modification; and an intervening region connecting the carboxy terminus of the NS4a domain to the amino terminus of the modified NS3 domain , or a polypeptide having at least 90% amino acid homology to said polypeptide , or a polypeptide having at least 90% amino acid identity to said polypeptide.2. The immunoassay reagent of claim 1 , wherein the modification comprises a substitution of one or more of amino acid residues 55 claim 1 , 79 and 137 of SEQ ID NO:4.3. The immunoassay reagent of claim 2 , wherein the modification comprises a substitution of alanine or glycine.4. The immunoassay reagent of claim 3 , wherein the modification comprises a substitution of alanine for amino acid residue 137.5. The immunoassay reagent of claim 1 , wherein the intervening region of the polypeptide has the amino acid sequence SGS.6. The immunoassay reagent of claim 1 , wherein the polypeptide has an amino acid sequence as shown in SEQ ID NO:2.7. The immunoassay reagent of bound to a solid support.8. A method of detecting antibodies to hepatitis C virus in a biological sample claim 1 , said method comprising: (a) providing the immunoassay reagent of ; (b) combining a biological sample with said immunoassay reagent under conditions which allow HCV antibodies claim 1 , when present in the biological sample claim 1 ...

Подробнее
Номер записи: 40
10-01-2019 дата публикации

POTENCY TEST FOR VACCINE FORMULATIONS

Номер: US20190011420A1
Автор: ALLEN MICHELLE, BRUDERER URS PETER, GARRETT MARK, THIJSSEN MARTINUS ANTONIUS JOHANNES
Принадлежит: Intervet Inc.

The invention relates to certain methods for the determination of an antigen content of a first antigen in a mixture comprising two or more antigens. The invention also relates to a potency test for an antigen in a combination vaccine. The method allows the determination of the antigen content in a mixture additionally comprising antibodies that are capable of binding with the antigen. 1. A method for the determination of an antigen content of a first antigen in a mixture of at least a composition comprising the first antigen and a composition comprising (i) a second antigen and (ii) antibodies that are capable of binding with the first antigen , the method comprising the steps of:a) dissociating antigen-antibody complexes in the mixture, formed between the first antigen and the antibodies; andb) determining the antigen content of the first antigen by means of an immunoassay.2Mycoplasma hyopneumoniae. The method of claim 1 , wherein the first antigen is a porcine circovirus type 2 (PCV-2) antigen and the second antigen is a antigen.3. The method of claim 1 , wherein the immunoassay is an ELISA (enzyme linked immunosorbant assay).4. The method of claim 1 , wherein the mixture is a ready-to-use vaccine formulation.5. The method of claim 1 , wherein the mixture is incubated with an acid solution to dissociate the antigen-antibody complexes.6. The method of claim 5 , wherein the acid solution is a citric acid solution.7. The method of claim 5 , wherein the mixture is incubated with the acid solution for at least 8 hours.8. The method of claim 5 , wherein the mixture is incubated at a ratio (v/v) between the acid solution and the mixture of at least 25 claim 5 , preferably 25-75 claim 5 , more preferably 25-50.9. The method of claim 5 , wherein the acid solution has a pH of 1.0-3.0.10Mycoplasma hyopneumoniaeM. hyo. A method for the determination of an antigen content of a porcine circovirus type 2 (PCV-2) antigen in a mixture of at least a composition comprising the PCV- ...

Подробнее
Номер записи: 41
10-01-2019 дата публикации

PROCESS FOR DETERMINING A HUMORAL RESPONSE IN AN IMMUNODEPRESSED PATIENT

Номер: US20190011446A1
Автор: BOUCHARD Ghislaine
Принадлежит: BIOMERIEUX

A determination method for determining, in an immunodepressed subject, a humoral response due to the presence of a target infectious agent, by detection, in a biological sample of the subject, of at least one target antibody that is susceptible of being produced by the subject when the latter is infected with or has been infected with the target infectious agent. Also, a determination method for determining a humoral response due to the presence of a target infectious agent from a biological sample from an immunodepressed or non-immunodepressed subject, in which the dilution ratio of the sample is selected as a function of the immunodepressed condition or otherwise of the subject concerned. 1. A determination method for determining , in an immunodepressed subject , a humoral response due to the presence of a target infectious agent , by detection , in a biological sample E1 of said subject , of at least one target antibody that is susceptible of being produced by said subject when the latter is infected with or has been infected with said target infectious agent , the method comprising the following steps:a) providing a volume V1 of the sample E1;b) diluting the volume V1 with a volume D1 of diluent, with a dilution ratio R1 that is equal to V1/(V1+D1), the dilution ratio R1 being higher than a dilution ratio R2 used for a non-immunodepressed subject, R2 being equal to V2/(V2+D2), with V2 and D2 respectively being the volume of the sample E2 and the volume of diluent used for a non-immunosuppressed subject, in a manner such as to obtain a diluted sample;c) detecting said at least one target antibody on the resulting diluted sample in order to draw a conclusion concerning the possible presence of the humoral response.2. A determination method according to claim 1 , characterized in that it has the following characteristics:providing a kit or device for detecting antibodies directed against said infectious agent, which is thus capable of determining the humoral ...

Подробнее
Номер записи: 42
03-02-2022 дата публикации

ANTI-HEPATITIS C VIRUS ANTIBODIES

Номер: US20220033479A1
Автор: ELIYAHU Sivan, ELMEDVI Shiri, Gal-Tanamy Meital, SHARABI Oz, Yaari Gur
Принадлежит: BAR ILAN UNIVERSITY

Provided are isolated monoclonal antibodies or any antigen-binding fragment thereof which bind to hepatitis C virus E2 protein (HCV E2). In particular the presently claimed subject matter concerns neutralizing anti HCV E2 antibodies, and their use for treating HCV infection. Furthermore, the presently claimed subject matter concerns methods for preparing neutralizing anti HCV scFv antibodies associated with HCV clearance. 1. An isolated monoclonal antibody or any antigen-binding fragment thereof which binds to hepatitis C virus E2 protein (HCV E2) , wherein said antibody is selected from a group consisting of:a. a monoclonal antibody comprising a heavy chain complementarity determining region (CDRH) 1 denoted by SEQ ID NO. 158, CDRH2 denoted by SEQ ID NO. 159, CDRH3 denoted by SEQ ID NO. 160, and the light chain complementarity determining region (CDRL) 1 denoted by SEQ ID NO. 163, a CDRL2 denoted by SEQ ID NO. 65, and a CDRL3 denoted by SEQ ID NO. 165, or a variant thereof;b. a monoclonal antibody comprising a CDRH1 denoted by SEQ ID NO. 168, CDRH2 denoted by SEQ ID NO. 169, CDRH3 denoted by SEQ ID NO. 170, and a CDRL1 denoted by SEQ ID NO. 173, a CDRL2 denoted by SEQ ID NO. 65, and a CDRL3 denoted by SEQ ID NO. 175, or a variant thereof;c. a monoclonal antibody comprising a CDRH1 denoted by SEQ ID NO. 108, CDRH2 denoted by SEQ ID NO. 109, CDRH3 denoted by SEQ ID NO. 110, and a CDRL1 denoted by SEQ ID NO. 113, a CDRL2 denoted by SEQ ID NO. 65, and a CDRL3 denoted by SEQ ID NO. 115, or a variant thereof;d. a monoclonal antibody comprising a CDRH1 denoted by SEQ ID NO. 78, CDRH2 denoted by SEQ ID NO. 79, CDRH3 denoted by SEQ ID NO. 80, and a CDRL1 denoted by SEQ ID NO. 83, a CDRL2 denoted by SEQ ID NO. 65, and a CDRL3 denoted by SEQ ID NO. 85, or a variant thereof;e. a monoclonal antibody comprising a CDRH1 denoted by SEQ ID NO. 59, CDRH2 denoted by SEQ ID NO. 60, CDRH3 denoted by SEQ ID NO. 61, and a CDRL1 denoted by SEQ ID NO. 64, a CDRL2 denoted by SEQ ID NO. 65, ...

Подробнее
Номер записи: 43
03-02-2022 дата публикации

HIGH SPECIFICITY AND SENSITIVITY IMMUNOSORBENT DIAGNOSTIC ASSAYS WITH SIMULTANEOUS RESOLUTION OF MULTIPLE ANTIBODY ISOTYPES

Номер: US20220034880A1
Автор: Tal Michal Caspi, Weissman Irving L.
Принадлежит:

Compositions and methods are provided for diagnosis of infections. The patterns of antibody isotype, subtype and glycosylation provide for a signature pattern that can identify infective agents and patient response to infection. Patients likely to benefit from therapeutic intervention can be discriminated from patients that have a low probability of responsiveness. Therapies are also provided. 1. A method of characterizing an immune response to a pathogen by an individual , the method comprising:collecting at least one antibody-containing sample from the individual;contacting said at least one antibody-containing sample from the individual with a diagnostic pathogen;contacting the diagnostic pathogen with one or more isotype-specific or glycosylation-specific reagents, which reagents are operably linked to a detectable moiety; andanalyzing the diagnostic pathogen for the presence of bound isotype-specific or glycosylation-specific reagents to determine the presence and type of pathogen-specific antibodies, wherein the presence and type is indicative of a pathogen infection and immune response.2. The method of claim 1 , wherein the diagnostic pathogen is an intact pathogen claim 1 , genetically modified to express a fluorophore.3. The method of claim 2 , wherein the fluorophore is a fluorescent protein.4. The method of claim 3 , wherein the fluorescent protein is selected from the group consisting of green fluorescent protein (GFP) claim 3 , red fluorescent protein (RFP) claim 3 , and analogs thereof.5. The method of any of - claim 3 , wherein the diagnostic pathogen is a live pathogen or a fixed pathogen.6. The method of any of - claim 3 , wherein the diagnostic pathogen is a clinical isolate or an environmental isolate.7. The method of any of - claim 3 , wherein the diagnostic pathogen is from a cell line or cell culture.8. The method of any of - claim 3 , wherein the diagnostic pathogen is further genetically modified to eliminate expression of proteins and other ...

Подробнее
Номер записи: 44
03-02-2022 дата публикации

METHODS AND REAGENTS FOR ZIKA VIRUS IMMUNOASSAYS

Номер: US20220034882A1
Автор: Patibandla Sai, Singh Krishna
Принадлежит: SIEMENS HEALTHCARE DIAGNOSTICS INC.

Disclosed herein are immunoassay methods and reagents for detecting anti-Zika IgM antibody in a biological sample from a subject and/or diagnosing Zika virus infection in a subject. Also disclosed are algorithms for implementing the disclosed methods. The disclosed immunoassay methods, reagents, and algorithms enable efficient and reliable qualitative detection of anti-Zika virus antibodies and rapid determination of presumptive positive results for Zika virus infection in human subjects. 1. A method of detecting an anti-Zika virus IgM antibody in a biological sample from a human subject , the method comprising a first immunoassay and , optionally , a second immunoassay , wherein the first immunoassay comprises: 'an anti-human IgG Fc antibody,', 'a) incubating the biological sample with'}a labeled Zika virus antigen, anda solid support comprising an anti-human IgM antibody,wherein, in the presence of an anti-Zika virus IgG antibody, an anti-Zika virus IgM antibody, or an anti-Zika virus IgG antibody and an anti-Zika virus IgM antibody in the biological sample, a complex I is formed, the complex I comprising (i) the anti-Zika virus IgG antibody, the anti-Zika virus IgM antibody, or the anti-Zika virus IgG antibody and the anti-Zika virus IgM antibody, (ii) the labeled Zika virus antigen, and (iii) the solid support comprising the anti-human IgM antibody; andb) detecting the complex I, the presence of which indicates the presence of the anti-Zika virus IgM antibody, the anti-Zika virus IgG antibody, or the anti-Zika virus IgG antibody and the anti-Zika virus IgM antibody in the biological sample, and if the complex I is detected, performing the second immunoassay, comprising: 'a solid support comprising an anti-human IgM antibody, and', 'c) incubating the biological sample with'}a labeled Zika virus antigen,wherein, in the presence of an anti-Zika virus IgM antibody in the biological sample, a complex II is formed, the complex II comprising (i) the solid support ...

Подробнее
Номер записи: 45
03-02-2022 дата публикации

COMPOSITIONS AND METHODS FOR DETERMINING CORONAVIRUS NEUTRALIZATION TITERS

Номер: US20220034885A1
Автор: Gibson Andy, Leinert, Mond James, SR. William Pat
Принадлежит:

The disclosure is directed to methods and kits for detecting neutralizing antibodies against a coronavirus (e.g., SARS-CoV-2) in a sample, such as a plasma sample or pooled plasma composition. The methods utilize a panel of SARS-CoV-2 neutralizing antibodies as a positive control. The kit may be a rapid detection kit that measures neutralizing antibodies using the provided methods. 1. A method of detecting coronavirus neutralizing antibodies in a sample , which method comprises:(a) contacting a sample with a solid support comprising a coronavirus cell receptor immobilized thereto to form a mixture;(b) contacting the mixture with a conjugate comprising a reporter molecule attached to a peptide comprising a receptor binding domain (RBD) of a coronavirus spike protein, whereby, if coronavirus neutralizing antibodies are present in the sample, the RBD binds to the coronavirus neutralizing antibodies and does not bind to the immobilized coronavirus cell receptor;(c) detecting and quantifying a signal from the reporter molecule, wherein the amount of detected signal is inversely proportional to the amount of coronavirus neutralizing antibodies present in the sample; and(d) performing steps (a)-(c) on a positive control comprising a panel of one or more coronavirus neutralizing monoclonal antibodies instead of the sample, and comparing the quantified signal of the positive control to the quantified signal of the sample to determine coronavirus neutralizing antibody capacity of the sample.2. A method of detecting coronavirus neutralizing antibodies in a sample , which method comprises:(a) contacting a sample with a conjugate comprising a reporter molecule attached to a peptide comprising a receptor binding domain (RBD) of a coronavirus spike protein to form a mixture, wherein the RBD binds to coronavirus neutralizing antibodies if present in the sample;(b) contacting the mixture with a solid support comprising a coronavirus cell receptor immobilized thereto, whereby, if ...

Подробнее
Номер записи: 46
03-02-2022 дата публикации

IMMUNOASSAY FOR SARS-CoV-2 ANTIBODIES

Номер: US20220034904A1
Автор: Govind Bhavesh, Guiffo Djoko Lionel Gilles, Janeczko Richard, Vashist Sandeep Kumar
Принадлежит:

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the strain of coronavirus that causes coronavirus disease 2019 (COVID-19), the respiratory illness responsible for the COVID-19 pandemic. Antibodies produced from an immune response against SARS-CoV-2 infection are used to analyze prior exposure to the virus. The present invention provides methods for detecting antibodies in response to SARS-CoV-2 infection in a single multiplex immunoassay. 1. A substrate comprising at least two capture elements specific for SARS-CoV-2 on the substrate , each capture element corresponding to and being able to bind a target analyte , the substrate further optionally comprising a plurality of control elements comprising: a) at least one fiduciary marker , b) at least one negative control to monitor background signal , c) at least one negative control to monitor assay specificity , d) at least one positive colorimetric control , e) at least one positive control to monitor assay performance and any combination thereof.2. The substrate of claim 1 , wherein the capture elements bind target analytes claim 1 , wherein the target analytes are indicative of antibodies produced in response to SARS-CoV-2 infection.3. The substrate of claim 1 , wherein the capture elements are selected from a protein claim 1 , a protein fragment claim 1 , a peptide claim 1 , a polypeptide claim 1 , a polypeptide fragment claim 1 , an antibody claim 1 , an antibody fragment claim 1 , an antibody binding domain or any combination thereof.4. The substrate of claim 3 , wherein the capture elements are selected from a SARS-CoV-2 Membrane protein (MP) claim 3 , Nucleocapsid protein (NP) claim 3 , Spike protein (SP) claim 3 , or any combination thereof.5. The substrate of claim 3 , wherein the target analyte is a SARS-CoV-2 antibody claim 3 , fragment or binding domain thereof.6. The substrate of claim 1 , wherein the target analyte is selected from a protein claim 1 , a protein fragment claim 1 , an ...

Подробнее
Номер записи: 47
21-01-2016 дата публикации

Methods to Protect Against and Treat Multiple Sclerosis

Номер: US20160017022A1
Автор: FISCHETTI Vincent A., Rumah Kareem Rashid, Vartanian Timothy
Принадлежит:

The invention provides epsilon toxin (ETX) produced by type B or type D as a causative toxin for human multiple sclerosis (MS). The invention further identifies ETX binding receptor MAL for ETX mediated cell death and other toxin-logical activities in MS. Methods and compositions to prevent humans from multiple sclerosis (MS) and/or treating MS by directly or indirectly interfering with epsilon toxin (ETX), its binding receptor (e.g., MAL), or ETX-receptor interactions so as to inhibit or suppress downstream ETX mediated receptor signaling activities are provided. Also provided are various methods to detect, diagnose, monitor, assess multiple sclerosis (MS) by determining an expression level of ETX gene or its encoding protein in human patient suspected for and/or at risk for multiple sclerosis (MS).

Подробнее
Номер записи: 48
18-01-2018 дата публикации

Human neutralizing antibodies binding to influenza neuraminidase

Номер: US20180016348A1
Автор: Miriam Verena Bujny, Remko VAN DER VLUGT
Принадлежит: Janssen Vaccines and Prevention BV

Influenza neuraminidase (NA)-binding human antibodies, which are capable of neutralizing at least one influenza A virus strain containing NA of the N1 subtype, and antigen-binding fragments thereof are described. Certain antibodies or antigen-binding fragments described herein furthermore are capable of neutralizing at least one influenza A virus strain comprising NA of the N2 subtype. Also described is the use of said antibodies or antigen-binding fragments in the diagnosis, prophylaxis and/or treatment of influenza infection.

Подробнее
Номер записи: 49
21-01-2016 дата публикации

Molecules inhibiting the human immunodeficiency virus type 1 (hiv-1), method for the production thereof and applications of same

Номер: US20160017332A1
Автор: Alfredo Berzal Herranz, Carlos Briones Llorente, Francisco José SÁNCHEZ-LUQUE, Michael STICH, Susanna CUEVAS MANRUBIA
Принадлежит: Consejo Superior de Investigaciones Cientificas CSIC, Instituto Nacional de Tecnica Aeroespacial Esteban Terradas

The invention relates to an aptamer, the structure thereof comprising at least one nucleotide sequence 5′-GGCA(A/G)GGA-3′, that can specifically bind to the poly(A) hairpin of the 5′UTR region of the genome of the human immunodeficiency virus type 1 (HIV-1), providing the method for producing aptamers with said sequence by means of a combination of experimental techniques of in vitro selection of nucleic acids with computational techniques of sequence optimization. The invention also relates to a DNA gene structure for synthesizing said aptamers, preferably RNA. The invention further relates to the different uses of the above-mentioned aptamer, including the use thereof as a biosensor molecule for detecting and/or quantifying HIV-1, as an inhibitor of the production of viral particles of HIV-1, and to the application thereof in medicine, the invention also relating to a method for treating a disease caused by HIV-1, and to a pharmaceutical composition comprising said aptamer.

Подробнее
Номер записи: 50
19-01-2017 дата публикации

DIAGNOSTIC REAGENTS FOR IMPROVED IN VIVO OR IN VITRO CELL-MEDIATED IMMUNOLOGICAL DIAGNOSIS OF TUBERCULOSIS

Номер: US20170016897A1
Автор: Aagaard Claus, Agger Else Marie, ANDERSEN Peter Lawætz, Hoff Søren Tetens, Rosenkrands Ida
Принадлежит: STATENS SERUM INSTITUT

The present invention discloses in vitro and in vivo diagnostic methods with enhanced specificity and sensitivity for the detection of . The diagnostic re agents of the present invention can replace former mixtures/cocktails/pools of antigens comprising ESAT-6 but including ESAT6 improves the diagnosis even further. 1: A diagnostic composition comprising a mixture of substantially pure polypeptides comprised of amino acid sequences selected froma)Rv3874 (SEQ ID NO: 1), Rv3615 (SEQ ID NO: 2), and one or more amino acid sequences selected from Rv3865 (SEQ ID NO: 3), Rv2348 (SEQ ID NO: 4), Rv3614 (SEQ ID NO: 5), Rv2654 (SEQ ID NO: 6) and Rv3877 (SEQ ID NO: 7);b)fragments of Rv3874 (SEQ ID NO: 1), fragments of Rv3615 (SEQ ID NO: 2), and fragments of one or more amino acid sequences selected from Rv3865 (SEQ ID NO: 3), Rv2348 (SEQ ID NO: 4), Rv3614 (SEQ ID NO: 5), Rv2654 (SEQ ID NO: 6) and Rv3877 (SEQ ID NO: 7), said fragments comprising immunogenic epitopes from said amino acid sequences;c)a selected mixture of amino acids according to a) or a selected mixture of fragments according to b), wherein each of the amino acids in said selected mixture according to a) or each of the fragments in said selected mixture according to b) have at least 80% sequence identity to an amino acid of a) or a fragment of b) and at the same time is immunogenic.2: A diagnostic composition according to claim 1 , comprising Rv3874 (SEQ ID NO: 1) claim 1 , Rv3615 (SEQ ID NO: 2) and Rv3865 (SEQ ID NO: 3) or fragments comprising immunogenic epitopes hereof.3: A diagnostic composition according to claim 1 , comprising Rv3874 (SEQ ID NO: 1) claim 1 , Rv3615 (SEQ ID NO: 2) and Rv2348 (SEQ ID NO: 4) or fragments comprising immunogenic epitopes hereof.4: A diagnostic composition according to claim 1 , comprising Rv3874 (SEQ ID NO: 1) claim 1 , Rv3615 (SEQ ID NO: 2) and Rv3877 (SEQ ID NO: 7) or fragments comprising immunogenic epitopes hereof.5: A diagnostic composition according to claim 1 , comprising ...

Подробнее
Номер записи: 51
21-01-2016 дата публикации

TRANSMISSION-LINE-COUPLED MICROFLUIDIC-CHIP TECHNOLOGY FOR ELECTROMAGNETIC SENSING OF BIOMOLECULES AND BIOPARTICLES

Номер: US20160018393A1
Автор: Brown Elliott R., Mendoza Edgar A., Viveros Leamon
Принадлежит: WRIGHT STATE UNIVERSITY

A coplanar waveguide transmission line for use in detecting biomolecules and bioparticles is provided that includes a signal conductor disposed on a top surface of the dielectric substrate, a ground conductor disposed on the top surface of the dielectric substrate on each side of the signal conductor, a continuous gap defined between the signal conductor and each of the ground conductors, micro-channels disposed below a top surface of the dielectric substrate, and reservoirs disposed below the top surface of the substrate.

Подробнее
Номер записи: 52
18-01-2018 дата публикации

Modified Indirect Enzyme Linked Immunosorbent Assay Optimal for Monitoring Acute and Long Term Carrier Infections of Diverse Babesia bovis Strains

Номер: US20180017556A1
Автор: Chung Chungwon J., Suarez Carlos E., Wilson Carey L.
Принадлежит:

We have developed a modified indirect ELISA (MI-ELISA) using the spherical body protein-4 (SBP4) of to detect antibody against diverse isolates through all infection stages in cattle. This SBP4 MI-ELISA was evaluated for sensitivity and specificity against field sera and sera from cattle infected experimentally with various doses and isolates as well as in detecting acute and persistent infection. The diagnostic specificity of the SBP4 MI-ELISA using IFA-negative sera was 100%, significantly higher than the RAP-1 cELISA (90.4%); the diagnostic sensitivity of the SBP4 MI-ELISA was 98.7% using the IFA-positive sera, in contrast to that of the RAP-1 cELISA at 60%. Results demonstrate excellent diagnostic sensitivity and specificity of the novel SBP4 MI-ELISA for cattle with acute and long-term carrier infections. Use of the SBP4 MI-ELISA assay in countries that have -endemic herds will be pivotal in preventing the spread of this disease to non-endemic herds. 1Babesia bovis,. A recombinant rGST-SBP4 fusion protein comprising glutathione S-transferase (GST) and spherical body protein-4 (SBP4) antigen ofwherein the SBP4 has been modified by having the signal sequence for SBP4 deleted.2. The recombinant rGST-SBP4 fusion protein of claim 1 , wherein said rGST-SBP4 fusion protein consists of the amino acid sequence of SEQ ID NO:1.3. The recombinant rGST-SBP4 fusion protein of claim 1 , wherein said rGST-SBP4 fusion protein consists of an amino acid sequence having at least 95% identity to SEQ ID NO:1.4. A cDNA molecule encoding the protein of .5Babesia bovisB. bovis. A method of detecting antibodies to in an individual claim 1 , the method comprising the steps of: (a) contacting a biological sample from said individual with the rGST-SBP4 fusion protein antigen according to for a time and under conditions sufficient to form antigen/antibody complexes and (b) detecting in the biological sample the presence of antibodies that bind to the rGST-SBP4 fusion protein antigen claim 1 ...

Подробнее
Номер записи: 53
18-01-2018 дата публикации

Antibodies to the Surface of Toxoplasma Gondii Oocysts and Methods of Use Thereof

Номер: US20180017557A1
Автор: Conrad Patricia, Fritz Heather
Принадлежит:

The present disclosure provides antibodies that bind the surface of oocysts, methods for using such antibodies and kits and devices for practicing such methods. Such antibodies, methods, kits and devices find use in detection of oocysts and the isolation of such oocysts from samples including environmental samples, food-based samples, diagnostic samples, and the like. 1Toxoplasma gondii. A method of detecting an intact oocyst in a sample , the method comprising:{'i': T. gondii', 'T. gondii', 'T. gondii, 'a) contacting a sample suspected of containing a oocyst with an antibody that specifically binds a protein on the outer wall of an intact oocyst under conditions sufficient to form an immunocomplex of the antibody with the intact oocyst; and'}b) detecting the presence or absence of the immunocomplex comprising the antibody.2T. gondii. The method according to claim 1 , wherein the sample has not been pre-processed to disrupt the oocyst.3. The method according to claim 2 , wherein the pre-processing comprises mechanical processing.4. The method according to any one of - claim 2 , wherein the pre-processing comprises chemical processing.5T. gondiiHammondiaEimeriaIsosporaGiardiaCryptosporidium. The method according to any one of the preceding claims claim 2 , wherein the sample is further suspected of containing an oocyst or cyst of an organism related to selected from the group consisting of: spp. claim 2 , spp. claim 2 , spp. claim 2 , spp. and spp.6. The method according to any one of the preceding claims claim 2 , wherein the antibody is detectably labeled.7. The method according to any one of the preceding claims claim 2 , wherein the antibody is attached to a support.8. The method according to claim 7 , wherein the support is a bead.9. The method according to claim 8 , wherein the bead comprises a surface bound capture agent claim 8 , and the monoclonal antibody is attached to the support by binding to the capture agent.10. The method according to any one of the ...

Подробнее
Номер записи: 54
18-01-2018 дата публикации

PREDICTING S. AUREUS DISEASE

Номер: US20180017559A1
Автор: MAGYARICS Zoltán, Nagy Eszter, Rouha Harald, STULIK Lukas
Принадлежит: ARSANIS BIOSCIENCES GMBH

The invention relates to a method for the prediction of disease in a subject heavily colonized by but not showing any symptom of disease, said method comprising the step of determining the alpha haemolysin level in a biological sample of said subject as compared to a standard or reference control, wherein an elevated alpha haemolysin level or activity is indicative of the onset of disease. 1S. aureusS. aureusS. aureusS. aureusS. aureus.. A method of diagnosing and treating an disease in a subject heavily colonized by but not showing any symptom of disease , said method comprising (i) determining the alpha haemolysin level in a biological sample of said subject as compared to a standard or reference control , wherein an elevated alpha haemolysin level is indicative of the onset of disease , and (ii) treating the subject with elevated alpha haemolysin with an antibiotic targeting2S. aureus. The method of claim 1 , wherein the subject is not showing any symptom of disease which is any of the clinical symptoms leading to diagnosis of bronchitis claim 1 , pneumonia claim 1 , sepsis claim 1 , or chronic wound infection.3S. aureus. The method of claim 1 , wherein the alpha haemolysin level is indicative of the onset of disease claim 1 , which is selected from the group consisting of bronchitis claim 1 , pneumonia claim 1 , sepsis claim 1 , or chronic wound infection.4S. aureusS. aureus.. The method of claim 1 , wherein the subject is colonized by as determined by a method of determining the presence of the bacterium or a bacterial marker indicative of5. The method of claim 1 , wherein the subject is colonized in the nose or nasopharynx claim 1 , and the subject is undergoing intubation.6S. aureus. The method of claim 1 , wherein the subject is a mechanically ventilated patient and heavily colonized with in the lower airways.7. The method of claim 1 , wherein the biological sample is a body fluid or tissue sample.8. The method of claim 1 , wherein said determination of the ...

Подробнее
Номер записи: 55
17-01-2019 дата публикации

METHOD FOR DIAGNOSING, TREATING, OR PREVENTING MOOD DISORDERS

Номер: US20190018022A1
Автор: KOBAYASHI Nobuyuki, KONDO Kazuhiro, Oka Naomi
Принадлежит:

An embodiment of the present invention provides a novel method for diagnosing, treating, or preventing a mood disorder. The method includes the step of measuring, by using a fusion protein, a level of the anti-fusion protein antibody in a biological sample. 1. A fusion protein comprising a SITH-1 protein and a CAML protein.2. The fusion protein as set forth in claim 1 , wherein:an N-terminal side of the CAML protein is bound to a C-terminal side of the SITH-1 protein.3. The fusion protein as set forth in claim 1 , wherein:a C-terminal side of the CAML protein is bound to an N-terminal side of the SITH-1 protein.4. A support to which a fusion protein recited in is immobilized.5. (canceled)6. A measurement method comprising the step of:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'measuring, by using a fusion protein recited in , a level of the anti-fusion protein antibody in a biological sample isolated from a subject.'}7. The measurement method as set forth in claim 6 , further comprising the step of:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'reacting a labeled anti-CAML antibody with a cell in which the fusion protein recited in is expressed.'}8. A diagnosis method for a mood disorder in a human subject claim 6 , comprising the step of:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'measuring an antibody level in a biological sample isolated from the human subject, the antibody level being an antibody level of an antibody (anti-fusion protein antibody) recognizing a fusion protein recited in .'}9. The diagnosis method as set forth in claim 8 , further comprising the step of:measuring a level of an antibody (anti-fusion protein antibody) recognizing the fusion protein,the fusion protein being a fusion protein in which an N-terminal side of the CAML protein is bound to a C-terminal side of the SITH-1 protein.10. The diagnosis method as set forth in claim 9 , using the fusion protein.11. The diagnosis method as set forth in claim 8 , further comprising ...

Подробнее
Номер записи: 56
28-01-2016 дата публикации

SIDEROPHORE-BASED IMMUNIZATION AGAINST GRAM-NEGATIVE BACTERIA

Номер: US20160022794A1
Автор: Chairatana Phoom, Nolan Elizabeth Marie, Perez-Lopez Araceli, Raffatellu Manuela, Sassone Corsi Martina
Принадлежит:

The present invention provides novel enterobactin-carrier protein conjugates and salmochelin-carrier protein conjugates, such as compounds of Formula (I), and salts thereof. The present invention also provides compositions, kits, and methods that involve the compounds of Formula (I) and are useful in inducing an immune response, treating a bacterial infection and/or inflammatory bowel disease in a subject, preventing a bacterial infection and/or inflammatory bowel disease in a subject, or inhibiting the growth of or killing a bacterium. 1. A compound of Formula (I):{'br': None, 'sub': 'n', 'CP-(L-Ent)\u2003\u2003(I)'}wherein CP is a carrier protein, L is a linker, Ent is enterobactin or a salmochelin, and n is a number between 1-400, inclusive;or a salt, hydrate, solvate, polymorph, co-crystal, tautomer, stereoisomer, or isotopically labeled derivative thereof.2. The compound of claim 1 , wherein L-Ent is attached to a lysine residue of the carrier protein.3Concholepas concholepas. The compound of claim 1 , wherein the carrier proteins is cholera toxin B subunit (CTB) claim 1 , keyhole limpet hemocyanin (KLH) claim 1 , ovalbumin (OVA) claim 1 , hemocyanin (CCH) or bovine serum albumin (BSA).4. The compound of claim 1 , wherein the linker is a poly(ethylene glycol) (PEG) molecule.5. The compound of claim 4 , wherein the PEG molecule has 1-10 PEG units (PEG-PEG).6. The compound of claim 5 , wherein the PEG molecule is a PEGmolecule.7. The compound of claim 1 , wherein at least one L-Ent is attached to each carrier protein (n is greater than 1).8. The compound of claim 7 , wherein n=5-300.9. The compound of claim 1 , wherein the Ent is complexed with iron.10. A composition comprising the compound of .11. The composition of claim 10 , further comprising an immunological adjuvant.12. (canceled)13. A method for inducing an immune response against an enterobactin or salmochelin molecule claim 10 , comprising{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'administering ...

Подробнее
Номер записи: 57
28-01-2016 дата публикации

Polypeptides for treating and/or limiting influenza infection

Номер: US20160024155A1
Автор: Baker David, Fleishman Sarel, Whitehead Timothy A.
Принадлежит:

Polypeptides are disclosed herein, which recognize and are strong binders to Influenza A hemagglutinin and can be used, for example, to treat and/or limit development of an influenza infection. 1. A polypeptide comprising an amino acid sequence according to general formula IIR1-R2-R3-R4-R5-R6-R7-R8-R9-Ala-R10-R11-Phe (SEQ ID NO: 83), whereinR1 is selected from the group consisting of Phe and Val;R2 is selected from the group consisting of Ser, Ala, Phe, Gly, Ile, Lys, Leu, Met, Asn, Pro, Gln, Arg, Thr, and Val;R3 is selected from the group consisting of Glu, and Asp;R4 is selected from the group consisting of Asn, His, Ile, Lys, Leu, Met, Arg, Ser, and Thr;R5 is selected from the group consisting of Leu, Phe, Ile, Met, Asn, Gln, and Val;R6 is selected from the group consisting of Ala, Asp, Lys, Met, Asn, Gln, Arg, Glu, and Val;R7 is selected from the group consisting of Phe, Asp, Asn, and Tyr;R8 is selected from the group consisting of Glu, Ala, Asp, Gly, His, Lys, Leu, Met, Asn, Gln, Arg, Ser, Thr, Val, and Tip;R9 is selected from the group consisting of Leu, Phe, Ile, Met, and Val;R10 is selected from the group consisting of Leu, Ile, Met, and Tyr; andR11 is selected from the group consisting of Ser, Ala, Gly, and Tyr;3. The polypeptide of claim 2 , wherein X1 comprises the amino acid sequence TNKDTPDRW-Z1-KVA (SEQ ID NO: 85) where Z1 is Ala claim 2 , Lys claim 2 , Arg claim 2 , Gly claim 2 , or Thr.4. The polypeptide of claim 2 , wherein general formula II is A1-R1-R2-R3-R4-R5-R6-R7-R8-R9-Ala-R10-R11-Phe-X1-R12-R13-X2-R14-B1 (SEQ ID NO: 86) claim 2 , wherein one or both of A1 and B1 are present claim 2 , and wherein:A1 comprises the amino acid sequence: Z2-ASTRGSGRPW-Z3 (SEQ ID NO: 87), wherein Z2 is absent or is Met, and Z3 is selected from group consisting of Gly, Arg, Lys, Asp andB1 comprises the amino acid sequence G-Z4-TPEEVKKHYE (SEQ ID NO: 88), where Z4 is R or K.10. The polypeptide of claim 1 , wherein the polypeptide comprises a detectable tag.11. An ...

Подробнее
Номер записи: 58
22-01-2015 дата публикации

INTERFERING PEPTIDES AND METHOD FOR DETECTING MICROORGANISMS

Номер: US20150024380A1
Автор: BETTSWORTH Florence, POTHION Catherine, Seigneres Béatrice
Принадлежит:

The invention relates to novel interfering peptides having peptide sequence S with between 7 and 12 amino acids, originating from the peptide sequence of an antigenic protein of a micro-organism M, the sequence S being aligned with a peptide sequence S′ with between 7 and 12 amino acids originating from the peptide sequence of a target protein of a micro-organism M′ that is different from the micro-organism M, provided that: sequences S and S′ have at least 50% identity over their length of 7 to 12 amino acids and at least 4 identical or analogous contiguous amino acids; and their length is identical or they have 1 or 2 different amino acids distributed at one and/or the other end of the sequences. The invention also relates to a method for the in vitro immunoassay-based detection of the presence of a micro-organism M′ or M in a biological sample. 1. An interfering peptide having peptide sequence S , of 7 to 12 amino acids , originating from the peptide sequence of an antigenic protein of a microorganism M , said sequence S being aligned with respect to a peptide sequence S′ , of 7 to 12 amino acids , originating from the peptide sequence of a target protein of a microorganism M′ different than the microorganism M , it being understood that said sequences S and S′ exhibit at least 50% identity over their length of 7 to 12 amino acids and at least 4 identical or analogous contiguous amino acids , that their length is identical or that they exhibit a difference of 1 or 2 amino acids distributed at one and/or the other end of said sequences , and that the peptide V7E having sequence SEQ ID No 2 is excluded.2. The interfering peptide as claimed in claim 1 , wherein the sequences S and S′ have from 8 to 10 amino acids.3. The interfering peptide as claimed in claim 1 , wherein the microorganism M′ is a virus or a bacterium.4. The interfering peptide as claimed in claim 1 , wherein the microorganism M′ is a virus and the microorganism M is a bacterium.5. The interfering ...

Подробнее
Номер записи: 59
26-01-2017 дата публикации

METHODS FOR CULTURE AND IDENTIFICATION OF MYCROBACTERIUM AVIUM SUBSPECIES IN CROHN'S DISEASE

Номер: US20170022542A1
Автор: Minardi Lawrence M., Zhang Peilin
Принадлежит:

Method and media for diagnosing Crohn's disease are provided. A method of diagnosing Crohn's disease in patients includes: obtaining a sample from an individual; culturing the sample to determine the presence or absence of subspecies (MAH) in the sample; and diagnosing the individual with Crohn's disease based on the determining the presence of MAH in the sample. 1. A method of diagnosing Crohn's disease in patients , comprising:obtaining a sample from an individual;{'i': Mycobacterium avium', 'hominissuis, 'determining the presence or absence of subspecies (MAH) in the sample; and'}diagnosing the individual with Crohn's disease based on the determining the presence of MAH in the sample.2. The method of claim 1 , wherein the obtaining the sample comprises obtaining whole blood from the individual claim 1 , and further comprising preparing the sample prior to the determining.3. The method of claim 2 , wherein the preparing the sample comprises:removing plasma proteins from the sample; andlysing red blood cells of the sample.4. The method of claim 3 , further comprising culturing the prepared sample using three different media.5. The method of claim 4 , wherein the determining comprising using PCR direct sequencing to detect the presence of both IS1245 and 16S rDNA in an isolate of the cultured sample.6. The method of claim 1 , further comprising culturing the sample using a liquid medium comprising:Middlebrook 7H9;Yeast extract;Glycerol;Sucrose;Tween 80;Mycobactin J;Oleic acid; andNAD.7. The method of claim 6 , wherein the liquid medium is composed of:Middlebrook 7H9 0.47% volume/volume;Yeast extract 0.1% volume/volume;Glycerol 0.5% volume/volume;Sucrose 0.2% volume/volume;Tween 80 0.05% volume/volume;Mycobactin J 2 μg/ml weight/volume;Oleic acid 0.1% volume/volume; andNAD 20 μg/ml weight/volume.8. The method of claim 1 , further comprising culturing the sample using a solid medium comprising:Middlebrook 7H10Yeast extract;Glycerol;Sucrose;Tween 80;Mycobactin J;Oleic ...

Подробнее
Номер записи: 60
25-01-2018 дата публикации

VMP-LIKE SEQUENCES OF PATHOGENIC BORRELIA SPECIES AND STRAINS

Номер: US20180022782A1
Автор: NORRIS Steven J.
Принадлежит:

The present invention relates to DNA sequences encoding Vmp-like polypeptides of pathogenic , the use of the DNA sequences in recombinant vectors to express polypeptides, the encoded amino acid sequences, application of the DNA and amino acid sequences to the production of polypeptides as antigens for immunoprophylaxis, immunotherapy, and immunodiagnosis. Also disclosed are the use of the nucleic acid sequences as probes or primers for the detection of organisms causing Lyme disease, relapsing fever, or related disorders, and kits designed to facilitate methods of using the described polypeptides, DNA segments and antibodies. 1. An isolated nucleic acid comprising a nucleotide sequence that encodes at least 12 contiguous amino acids of SEQ ID NO: 32.2. The isolated nucleic acid of claim 1 , wherein the nucleotide sequence encodes at least 35 contiguous amino acids of SEQ ID NO: 32.3. The isolated nucleic acid of claim 1 , wherein the nucleotide sequence encodes at least 50 contiguous amino acids of SEQ ID NO: 32.4. The isolated nucleic acid of claim 1 , wherein the nucleotide sequence encodes a peptide comprising SEQ ID NO: 32.5. The isolated nucleic acid of claim 1 , wherein the nucleic acid is an RNA segment.6. The isolated nucleic acid of claim 1 , wherein the nucleic acid comprises at least 50 contiguous nucleotides of SEQ ID NO: 31.7. The isolated nucleic acid of claim 1 , wherein the nucleic acid comprises at least 110 contiguous nucleotides of SEQ ID NO: 31.8. The isolated nucleic acid of claim 1 , wherein the nucleic acid comprises the nucleotide sequence of SEQ ID NO: 31.9. An isolated nucleic acid comprising a nucleotide sequence that encodes at least 12 contiguous amino acids of SEQ ID NO: 36.10. The isolated nucleic acid of claim 9 , wherein the nucleotide sequence encodes at least 35 contiguous amino acids of SEQ ID NO: 36.11. The isolated nucleic acid of claim 9 , wherein the nucleotide sequence encodes at least 50 contiguous amino acids of SEQ ID NO: ...

Подробнее
Номер записи: 61
28-01-2016 дата публикации

Materials and Methods for Assessing and Mapping Microbes and Microbial Biofilms on Wounds

Номер: US20160025724A1
Автор: PHILLIPS Priscilla Lorraine, SAMPSON Edith Marion, Schultz Gregory S.
Принадлежит:

The subject invention provides point-of-care assays for assessing the topographical distribution of microbial biofilm and/or specific microorganisms in wounds. 2. The kit claim 1 , according to claim 1 , wherein the membrane is a nylon membrane.3. The kit claim 1 , according to claim 1 , wherein the stain is alcian blue and/or ruthenium red.4. A method of mapping the spatial distribution of microorganism(s) and/or biofilm(s) in a wound comprising:contacting a membrane with the wound; andanalyzing the membrane to determine the spatial distribution of microorganism(s) and/or biofilm(s) in the wound.5. The method claim 4 , according to claim 4 , wherein the membrane non-specifically adsorbs biological molecules when contacted with the wound.6. The method claim 5 , according to claim 5 , wherein said method comprises at least one of the following steps: blocking the membrane; contacting the membrane with one or more dyes; rinsing the membrane; and observing the membrane to determine the location(s) of biofilm(s) and/or microorganism(s).7. The method claim 5 , according to claim 5 , wherein claim 5 , after the membrane is contacted with the wound claim 5 , the membrane is contacted with a plurality of detection ligand molecules that are specific to certain microbial class(es) claim 5 , genera claim 5 , and/or species.8. The method claim 7 , according to claim 7 , wherein at least one detection ligand molecule is targeted to a component found in extracellular matrix of microbial biofilm claim 7 , a polyanionic bacterial exopolysaccharide claim 7 , poly-β-(1-6)-N-acetyl-D-glucosamine claim 7 , alginic acid claim 7 , or a component that is specific to certain microbial classes claim 7 , genera claim 7 , and/or species.9. The method claim 5 , according to claim 5 , wherein the membrane is a nylon membrane.10. The method claim 9 , according to claim 9 , wherein the membrane is a positively charged membrane.11. The method claim 4 , according to claim 4 , wherein the membrane ...

Подробнее
Номер записи: 62
28-01-2016 дата публикации

Automated imaging and analysis of the hemagglutination inhibition assay (hai)

Номер: US20160025727A1
Автор: Michael Nguyen, Robert Parkhill
Принадлежит: Sanofi Pasteur VaxDesign Corp

A system and method provide for high through put determination of agglutination states. The system includes a rotating table and multiple plate tilting stations. The system also includes one or more optical paths positioned to image entire plate arrays in tilted and/or untilted configurations. The system preferably includes image analysis software to analyze an image of an array of test wells and determine an agglutination state of each well based on the image analysis.

Подробнее
Номер записи: 63
26-01-2017 дата публикации

ANTI-T. CRUZI ANTIBODIES AND METHODS OF USE

Номер: US20170023568A1
Автор: Brophy Susan E., Hawksworth David J., Shah Dinesh O., Siegel Robert W., Tieman Bryan C., Tu Bailin, Tyner Joan D., Ziemann Robert N.
Принадлежит:

The present disclosure is directed to reagents and methods of using the reagents to detect epitopes of 1T. cruziT. cruzi. An immunodiagnostic reagent comprising one or more antibodies that specifically bind to a diagnostically relevant region of a polypeptide , wherein said one or more antibodies are selected from the group consisting of an antibody specific for polypeptides comprised by FP3 , Pep2 , FP10 and FRA polypeptides.2. The immunodiagnostic reagent according to claim 1 , wherein said immunodiagnostic reagent comprises two or more of said antibodies.3. The immunodiagnostic reagent according to claim 1 , wherein said immunodiagnostic reagent comprises an antibody selected from the group consisting of:{'i': T. cruzi', 'T. cruzi, 'sub': a', 'd', 'D, 'sup': 5', '−1', '−1', '6', '−1', '−1', '−3', '−1', '−1', '−1', '10', '−7, 'an antibody that specifically binds to a diagnostically relevant region of a polypeptide, wherein the polypeptide is FRA and further wherein said antibody has at last one binding constant selected from the group consisting of: an association rate constant (k) between about 7.0×10Msto about 7.0×10Ms, an dissociation rate constant (k) between about 4.0×10sto about 3.0×10sand an equilibrium dissociation constant (K) between about 5.7×10M to about 4.3×10M;'}{'i': T. cruzi', 'T. cruzi, 'sub': a', 'd', 'D, 'sup': 6', '−1', '−1', '6', '−1', '−1', '−3', '−1', '−2', '1', '10', '−8, '(b) an antibody that specifically binds to a diagnostically relevant region of a polypeptide, wherein the polypeptide is Pep2 and further wherein said antibody has at least one binding constant selected from the group consisting of: an association rate constant (k) between about 1.0×10Msto about 8.0×10Ms; an dissociation rate constant (k) between about 6.0×10sto about 4.0×10sand an equilibrium dissociation constant (K) between about 7.5×10M to about 4.0×10M;'}{'i': T. cruzi', 'T. cruzi, 'sub': a', 'd', 'D, 'sup': 4', '−1', '−1', '5', '−1', '−1', '−4', '−1', '−4', '−1', '− ...

Подробнее
Номер записи: 64
26-01-2017 дата публикации

DIAGNOSTIC DEVICE AND METHOD FOR DETECTION OF STAPHYLOCOCCUS INFECTION

Номер: US20170023569A1
Автор: Daiss John L., KATES Stephen L., NISHITANI Kohei, Schwarz Edward M.
Принадлежит: UNIVERSITY OF ROCHESTER

Disclosed herein are diagnostic devices, kits, and methods for the detection of an active infection in an individual. Utilizing a sample from the individual, antibodies specific for one or more polypeptides are detected, where the detection of a threshold number of antibodies specific for one or more polypeptides indicates the presence of an active infection. Exemplary panels of polypeptides that can be used with a high degree of specificity and sensitivity are disclosed. 1. A diagnostic device comprising:{'i': 'Staphylococcus', 'a substrate comprising a plurality of discrete sites and one of a plurality of polypeptides present at each of the plurality of discrete sites, each of the polypeptides comprising an epitope that binds specifically to an antibody present in a sample from an individual having an active infection,'}{'i': 'Staphylococcus', 'wherein, upon exposure to the sample of an individual, the specific binding of a threshold number of the plurality of polypeptides to antibodies in the sample indicates the presence of an active infection.'}2StaphylococcusStaphylococcusS. aureus, S. epidermidis, S. lugdunensis, S. saprophyticus, S. haemolyticus, S. caprae,S. simiae.. The diagnostic device according to claim 1 , wherein the infection is caused by a strain selected from the group consisting of and3. (canceled)4StaphylococcusStaphylococcus aureus. The diagnostic device according to claim 1 , wherein the plurality of polypeptides comprise three or more of polypeptides selected from the group of a glucosaminidase (Gmd) protein or polypeptide claim 1 , an amidase (Amd) protein or polypeptide claim 1 , an iron-regulated surface determinant protein A (IsdA) protein or polypeptide claim 1 , an iron-regulated surface determinant protein B (IsdB) protein or polypeptide claim 1 , an iron-regulated surface determinant protein H (IsdH) protein or polypeptide claim 1 , a Clumping Factor A (ClfA) protein or polypeptide claim 1 , a Clumping Factor B (ClfB) protein or ...

Подробнее
Номер записи: 65
26-01-2017 дата публикации

Compositions And Methods For Immunodominant Antigens of Mycobacterium Tuberculosis

Номер: US20170023586A1
Автор: Felgner Philip, Gennaro Maria Laura, Liang Xiaowu
Принадлежит:

Contemplated compositions, devices, and methods are drawn to various antigens from the pathogen and their use in vaccines, therapeutic agents, and various diagnostic tests. In particularly preferred aspects, the antigens are immunodominant and have quantified and known relative reactivities with respect to sera of a population infected with the pathogen, and/or have a known association with a disease parameter 1M. tuberculosisM. tuberculosis. A method for the detecting presence of antibodies which specifically bind to antigens of and which are present in a bodily fluid sample , comprising contacting the sample with antigens of , wherein the antigens are encoded by at least two of nucleic acids Rv3344c (SEQ ID NO: 939) , Rv3879c (SEQ ID NO: 962) , Rv3333c (SEQ ID NO: 938) , Rv3029c (SEQ ID NO:921) , Rv2396 (SEQ ID NO:876) , Rv2487c (SEQ ID NO:882) , Rv2162c (SEQ ID NO:863) , and Rv3043c (SEQ ID NO: 923) , and detecting antibodies which bind to the antigens.2M. tuberculosis. The method of claim 1 , wherein the antigens of are present in a crude expression extract or in partially purified form.3. The method of claim 1 , wherein the step of detecting the antibodies comprises use of a signal-generating anti-antibody.4M. tuberculosis. The method of claim 1 , wherein binding affinity of respective antibodies which specifically bind to antigens of are known and indicative of an activity state of tuberculosis.5M. tuberculosis. The method of claim 1 , wherein the antigens of are coupled to a solid phase prior to the step of contacting the sample with the antigens.6M. tuberculosis. The method of claim 5 , wherein the antigens of are coupled to the solid phase in an array.7. The method of claim 6 , wherein at least one of the antigens encoded by at least two of nucleic acids Rv3344c (SEQ ID NO: 939) claim 6 , Rv3879c (SEQ ID NO: 962) claim 6 , Rv3333c (SEQ ID NO: 938) claim 6 , Rv3029c (SEQ ID NO:921) claim 6 , Rv2396 (SEQ ID NO:876) claim 6 , Rv2487c (SEQ ID NO:882) claim 6 , ...

Подробнее
Номер записи: 66
23-01-2020 дата публикации

Proteins and nucleic acids useful in vaccines targeting Klebsiella pneumoniae

Номер: US20200023049A1
Автор: Mattsson Andreas Holm, Møller Niels Iversen
Принадлежит:

The present invention relates to proteins and nucleic acids derived from as well as therapeutic and diagnostic uses of the proteins and nucleic acids. 1K. pneumoniaeK. pneumoniae. A method for treatment or amelioration of infection with , in particular infection with multi-resistant , comprising administering to an individual in need thereof a therapeutically effective amount of a monoclonal antibody , which specifically binds to a polypeptide consisting ofa) an amino acid sequence SEQ ID NO: 18, orb) an amino acid sequence, which is a fragment of SEQ ID NO: 18 consisting of residues 23-597 or residues 276-597 or residues 23-275.2. The method according to claim 1 , wherein the monoclonal antibody specifically binds to claim 1 , residues 23-597 of SEQ ID NO: 18.3. The method according to claim 1 , wherein the monoclonal antibody specifically binds to claim 1 , residues 267-597 of SEQ ID NO: 18.4. The method according to claim 1 , wherein the monoclonal antibody specifically binds to claim 1 , residues 23-275 of SEQ ID NO: 18.5. The method according to claim 1 , wherein the monoclonal antibody is selected from a multi-domain antibody and a single-domain antibody of a llama or a camel.6. The method according to claim 5 , wherein the multi-domain antibody is selected from a murine antibody claim 5 , a humanized antibody claim 5 , and a fully human antibody.7. The method according to claim claim 5 , wherein the monoclonal antibody specifically binds to SEQ ID NO: 18.8K. pneumoniaeK. pneumoniae. A method for prophylaxis claim 5 , treatment or amelioration of infection with claim 5 , in particular infection with multi-resistant claim 5 , comprising administering to an individual in need thereof a therapeutically effective amount of an antibody analogue claim 5 , which specifically binds to a polypeptide consisting ofa) an amino acid sequence SEQ ID NO: 18, orb) an amino acid sequence, which is a fragment of SEQ ID NO: 18 consisting of residues 23-597 or residues 276-597 or ...

Подробнее
Номер записи: 67
10-02-2022 дата публикации

SARS-CoV-2 IgG/IgM ANTI-BODY DETECTION KIT

Номер: US20220042985A1
Автор: Jia Zhenghu, Zhang Boqing
Принадлежит:

Disclosed is a SARS-CoV-2 IgG/IgM detection kit. The kit includes a disposable test cassette and the disposable test cassette includes a base plate, a sample pad, a reaction pad and an absorbent pad. The sample pad, the reaction pad and the absorbent pad are sequentially connected and are provided on the base plate. The sample pad is coated with a colloidal gold-labeled recombinant SARS-CoV-2 S-RBD protein. The reaction pad is provided with a test line and a quality control line. The test line is coated with a mouse anti-human IgG and a mouse anti-human IgM and the quality control line is coated with a goat anti-mouse IgG. The kit provided herein can be used for rapid test of SARS-CoV-2 IgG/IgM, and has high accuracy, good stability and strong anti-interference performance. 1. A SARS-CoV-2 IgG/IgM detection kit , comprising a disposable test cassette , comprising: a base plate , a sample pad , a reaction pad , and an absorbent pad;wherein the sample pad, the reaction pad and the absorbent pad are sequentially connected and are provided on the base plate;the sample pad is coated a colloidal gold-labeled recombinant SARS-CoV-2 S-RBD protein;the reaction pad is provided with a test line and a quality control line; the test line is coated with a mouse anti-human IgG and a mouse anti-human IgM; and the quality control line is coated with a goat anti-mouse IgG.2. The detection kit of claim 1 , wherein the test line is provided at a side of the reaction pad close to the sample pad; and the quality control line is provided at a side of the reaction pad close to the absorbent pad.3. The detection kit of claim 1 , wherein the sample pad and the absorbent pad both are an absorbent paper; and the reaction pad is a glass fiber membrane.4. The detection kit of claim 1 , further comprising: a dropper claim 1 , a desiccant and a sample diluent.5. The detection kit of claim 4 , wherein the sample diluent is a 0.01-0.015 M PBS with pH of 7.4±0.2.6. A method of preparing the ...

Подробнее
Номер записи: 68
10-02-2022 дата публикации

RAPID DIAGNOSIS OF PERITONITIS IN PERITONEAL DIALYSIS PATIENTS

Номер: US20220042988A1
Автор: Jiang Tao, Wang Changna
Принадлежит:

Described is an assay for diagnosing an infection such as peritonitis in a subject. The assay includes a binding molecule, such as an antibody that specifically binds to an inflammatory marker in a sample from the subject, and a second binding molecule that binds to a marker indicative of a pathogen in the sample. For diagnosing peritonitis in a subject, the pathogen will be at least one bacterium and/or fungus. Typically, the assay will be incorporated into a lateral flow device and may include a binding molecule that specifically binds to an antigen indicative of the presence of a specific pathogen species. The described assay(s) may further include filter(s), enriching antigen(s), and buffer(s). Also described are methods of diagnosing and treating peritonitis in a subject who is a peritoneal dialysis patient that include utilizing the herein described assay(s) or assay kit(s) to analyze the subject's peritoneal dialysis effluent. 1. An assay kit for diagnosing an infection in a subject , the assay kit comprising:at least one first binding molecule that specifically binds an inflammatory marker in a sample taken of the subject, wherein the inflammatory marker is selected from the group consisting of neutrophil gelatinase-associated lipocalin (NGAL), interleukin 1 (IL-1), interleukin 6 (IL-6), interleukin 8 (IL-8), tumor necrosis factor a (TNFα), and procalcitonin,at least one second binding molecule having a label that specifically binds to the selected inflammatory marker or to the at least one first binding molecule,at least one third binding molecule that specifically binds a marker indicative of the presence of a lipoteichoic acid (LTA) in the sample, andat least one fourth binding molecule having a label that specifically binds to the marker indicative of the presence of LTA in the sample or to the at least one third binding molecule.2. The assay kit of claim 1 , wherein the binding molecules have been incorporated into a lateral flow device.3. An assay kit ...

Подробнее
Номер записи: 69
10-02-2022 дата публикации

Triage biomarkers and uses therefor

Номер: US20220042989A1
Автор: Brian Andrew FOX, Dayle Lorand SAMPSON, Leo Charles Mchugh, Richard Bruce Brandon
Принадлежит: IMMUNEXPRESS PTY LTD

Disclosed are methods, apparatus, kits and compositions for determining the absence of a systemic bacterial infection (sepsis) in patients, particularly ones presenting to hospital emergency departments (ED) as outpatients, by measurement of the host immune response using peripheral blood. The are methods, apparatus, kits and compositions can be used in mammals for diagnosing, making treatment decisions, determining the next procedure or diagnostic test, or management of patients suspected of having an infection, including those presenting with fever or other signs of systemic inflammation. More particularly, peripheral blood RNA and protein biomarkers are disclosed that are useful for distinguishing between the host immune response to bacteria compared to the host immune response to other causes of systemic inflammation including trauma, burns, autoimmune disease, asthma, anaphylaxis, arthritis, obesity and viral infections. As such, the biomarkers are useful for distinguishing bacterial-associated systemic inflammatory response syndrome from non-bacterial systemic inflammation to provide clinicians with strong negative predictive value (>95%) so that sepsis can be excluded as a diagnosis in patients presenting to ED with clinical signs of systemic inflammation.

Подробнее
Номер записи: 70
23-01-2020 дата публикации

ANTIGENIC TRIPEPTIDES DERIVED FROM MYCOBACTERIUM AVIUM SUBSP. PARATUBERCULOSIS S-TYPE STRAINS, DERIVATIVES AND USES THEREOF

Номер: US20200024307A1
Автор: Bannantine John P., BAY Sylvie, BIET Franck, ETIENNE Gilles
Принадлежит:

The present invention is directed to an isolated synthetic tripeptide of formula H-D-Phe-N-Methyl-L-Val-L-Ala-OMe (SEQ ID NO:1), or a derivative thereof, and to the corresponding lipotripeptides, which are specific to subsp. (Map) S-type strain, as well as derivatives and conjugates thereof. The invention also concerns the use of these antigens in different methods and tests for detecting Map infection, especially by detecting humoral response and cell mediated response of infected animals. The invention is also directed to a genetic signature of Map and a mass spectrometry and NMR spectroscopy signature of Map presence or infection. 1. An isolated synthetic tripeptide chosen from the group consisting in:a. a tripeptide of formula H-D-Phe-N-Methyl-L-Val-L-Ala-OMe (SEQ ID NO:1),b. a tripeptide of formula H-L-Phe-N-Methyl-L-Val-L-Ala-OMe (SEQ ID NO:2),c. a tripeptide of formula H-D-Phe-L-Val-L-Ala-OMe (SEQ ID NO:3);d. a tripeptide of formula H-D-Phe-N-Methyl-L-Val-L-Ala-OH (SEQ ID NO:4);e. a tripeptide of formula H-L-Phe-L-Val-L-Ala-OMe (SEQ ID NO:5);f. a tripeptide of formula H-D-Phe-L-Val-L-Ala-OH (SEQ ID NO:6);g. a tripeptide of formula H-L-Phe-N-Methyl-L-Val-L-Ala-OH (SEQ ID NO:7) andh. a tripeptide of formula H-L-Phe-L-Val-L-Ala-OH (SEQ ID NO:8).2. An isolated synthetic tripeptide variant of the tripeptide according to claim 1 , which is derived from the tripeptide by substitution of the L-Val by D-Val and/or substitution of L-Ala by D-Ala claim 1 , and/or N-alkylation of one or more of Phe claim 1 , Val and Ala claim 1 , and/or the retro-inverso sequence and/or a peptidomimetic of the tripeptide with modified backbone or linkage.3. An isolated synthetic tripeptide conjugate consisting in or comprising a tripeptide according to claim 1 , wherein the Phenylalanine at the N-terminus is N-acylated with a Cto Cacyl moiety claim 1 , which is not a fatty acid moiety.4. An isolated synthetic tripeptide conjugate consisting in or comprising a tripeptide according to ...

Подробнее
Номер записи: 71
23-01-2020 дата публикации

ANTIBODY

Номер: US20200024332A1
Автор: Thornton Christopher
Принадлежит:

The invention relates to antibodies to species and to methods of producing those antibodies. The invention also relates to the use of such antibodies in identifying the presence of the species and to methods of treating an infection with the species. 1. A hybridoma deposited under accession number ECACC 08120202.2. An antibody which may be obtained by culture of the hybridoma of claim 1 , or a functional fragment of such an antibody.3Aspergillus. An antibody claim 1 , or antibody fragment or other molecule capable of specifically binding to claim 1 , that antibody claim 1 , fragment or binding molecule comprising a CDR claim 1 , light chain claim 1 , heavy chain claim 1 , light chain variable region claim 1 , heavy chain variable region or antigen binding region claim 1 , especially Fab region claim 1 , that shows substantial homology with the corresponding region of the antibody according to the second aspect of the invention.4. An antibody according to comprising a CDR comprising an amino acid sequence having substantial homology to an amino acid sequence selected from the sequences shown in .5. An antibody according to claim 4 , comprising a first CDR comprising an amino acid sequence having substantial homology to the amino acid sequence shown in ;{'figref': {'@idref': 'DRAWINGS', 'FIGS. 21 or 22'}, 'a second CDR comprising an amino acid sequence having substantial homology to an amino acid sequence selected from the sequences shown in ; and'}{'figref': {'@idref': 'DRAWINGS', 'FIG. 24'}, 'a third CDR comprising an amino acid sequence having substantial homology to the amino acid sequence shown in .'}6. An antibody according to comprising a first CDR comprising an amino acid sequence having substantial homology to the amino acid sequence shown in ;{'figref': {'@idref': 'DRAWINGS', 'FIG. 23'}, 'a second CDR comprising an amino acid sequence having substantial homology to the amino acid sequence shown in ; and'}{'figref': {'@idref': 'DRAWINGS', 'FIG. 25'}, 'a third ...

Подробнее
Номер записи: 72
24-01-2019 дата публикации

MYCOBACTERIUM TUBERCULOSIS SPECIFIC PEPTIDES FOR DETECTION OF INFECTION OR IMMUNIZATION IN NON-HUMAN PRIMATES

Номер: US20190025302A1
Автор: Luke Kimberly
Принадлежит:

The present invention relates to novel peptides that may be used in whole or in combination for the detection of infection. In particular, the present invention relates to compositions and methods involving detection of antibodies contained in the blood of non-human primates that arise from an infection from or vaccination using an epitope specific inoculation. More particularly, the present invention provides a means to distinguish early, active, and latent infection. More particularly, the present invention describes an immunological diagnostic mechanism for the detection of infection. 1. An immunoassay device comprising one or more capture reagents comprising a peptide selected from the group consisting of SEQ ID NOs.1-149.2. The immunoassay device of claim 1 , wherein said device comprises two or more capture reagents claim 1 , each comprising a different peptide selected from the group consisting of SEQ ID NOs.1-149.3. The immunoassay device of claim 1 , wherein said one or more capture reagents comprise a polypeptide R-X-R claim 1 , wherein X is a peptide selected from the group consisting of SEQ ID NOs.1-149 claim 1 , Ris selected from the group consisting of the amino terminus of said polypeptide claim 1 , an amino acid or a polypeptide chain claim 1 , and Ris selected from the group consisting of the amino terminus of said polypeptide claim 1 , an amino acid or a polypeptide chain.4. The immunoassay device of claim 8 , wherein Ris a polypeptide chain of from about 2 to about 100 amino acids in length.5. The immunoassay device of claim 8 , wherein Ris a polypeptide chain of from about 2 to about 100 amino acids in length.6. The immunoassay device of claim 1 , further comprising a surface having at least one capture agent displayed thereon.7. The immunoassay device of claim 1 , wherein said device comprises two or more two or more capture reagents comprising a peptide selected from the group consisting of SEQ ID NOs.141 claim 1 , 145 claim 1 , 147 claim 1 , ...

Подробнее
Номер записи: 73
28-01-2021 дата публикации

LISTERIA-MONOCYTOGENES DETECTION METHOD

Номер: US20210024979A1
Автор: HARADA Yoshitaka, Seto Yasuhiro, TAKASAKI Kazuto, TSUNA Mika
Принадлежит:

Novel means that enables detection of the bacterium alone distinctly from other bacteria belonging to the genus with sufficiently high accuracy is disclosed. The present inventors intensively analyzed the genome of the bacterium to identify two genes (the lmo0084 gene and the lmo2736 gene) as target regions with which the bacterium can be specifically detected distinctly from other bacteria belonging to the genus utilizing a nucleic acid amplification method. By a further intensive study of the base sequences of these two genes, primer setting regions for highly accurate, specific detection of the bacterium alone were identified, and preferred particular examples of PCR primer sets, LAMP primer sets, and real-time PCR primer-probe sets were established. 1Listeria monocytogenesListeria monocytogenes:. A primer set for detection of , comprising any of the following primer sets for amplification of a partial region of lmo0084 gene or lmo2736 gene of(A-1) a set of a forward primer containing in its 3′-side the base sequence of SEQ ID NO:26 or a sequence which is the same as said base sequence except that not more than 4 bases are substituted at a genetic polymorphism site(s) in said base sequence, and a reverse primer containing in its 3′-side the base sequence of SEQ ID NO:30 or a sequence which is the same as said base sequence except that not more than 4 bases are substituted at a genetic polymorphism site(s) in said base sequence;(A-2) a set of a forward primer containing in its 3′-side the base sequence of SEQ ID NO:26 or a sequence which is the same as said base sequence except that not more than 4 bases are substituted at a genetic polymorphism site(s) in said base sequence, and a reverse primer containing in its 3′-side the base sequence of SEQ ID NO:31 or a sequence which is the same as said base sequence except that not more than 4 bases are substituted at a genetic polymorphism site(s) in said base sequence;(A-3) a set of a forward primer containing in its 3 ...

Подробнее
Номер записи: 74
23-01-2020 дата публикации

ELECTROCHEMICAL IMMUNOSENSORS

Номер: US20200025753A1
Автор: Claussen Jonathan, Das Suprem, Iverson Brian D.
Принадлежит:

In a general aspect, an apparatus can include a first carbon nanotube array that is patterned to define a first electrode having a first plurality of electrode segments. The apparatus can also include a second carbon nanotube array that is patterned to define a second electrode having a second plurality of electrode segments. The second plurality of electrode segments can be interdigitated with the first plurality of electrode segments. The apparatus can further include a biorecognition agent disposed on a surface of the first electrode and disposed on a surface of the second electrode. The first plurality of electrode segments can each have a height-to-width aspect ratio of at least 1 to 1. 1. An apparatus comprising:a first carbon nanotube array that is patterned to define a first electrode having a first plurality of electrode segments;a second carbon nanotube array that is patterned to define a second electrode having a second plurality of electrode segments, the second plurality of electrode segments being interdigitated with the first plurality of electrode segments; anda biorecognition agent disposed on a surface of the first electrode and disposed on a surface of the second electrode,the first plurality of electrode segments each having a height-to-width aspect ratio of at least 1 to 1.2. The apparatus of claim 1 , wherein the first carbon nanotube array is a first vertically-aligned carbon nanotube array (VANTA) and the second carbon nanotube array is a second VANTA.3. The apparatus of claim 1 , wherein the biorecognition agent includes one of an antibody claim 1 , an aptamer or an enzyme.4. The apparatus of claim 1 , wherein the biorecognition agent includes an antibody specific to detection of an oncoprotein.5. The apparatus of claim 4 , wherein the oncoprotein is a CIP2A protein and the antibody is a PP2A cancerous inhibitor.6Staphylococcus aureus. The apparatus of claim 1 , wherein the biorecognition agent includes an antibody specific to detection of a ...

Подробнее
Номер записи: 75
23-01-2020 дата публикации

ANTIBODY, COMPOSITE, DETECTION DEVICE AND METHOD USING SAME

Номер: US20200025759A1
Автор: IKEUCHI EMINA
Принадлежит:

The present invention is an antibody including an amino acid sequence, wherein the amino acid sequence includes, in an N- to C-direction, the following structural domains: 1. An antibody including an amino acid sequence , wherein the amino acid sequence includes , in an N- to C-direction , the following structural domains:{'br': None, 'N-FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4-C'} FR denotes a framework region amino acid sequence and CDR denotes a complementary determining region amino acid sequence;', 'the CDR1 includes an amino acid sequence represented by SEQ ID NO: 1;', 'the CDR2 includes an amino acid sequence represented by SEQ ID NO: 2; and', 'the CDR3 includes an amino acid sequence represented by SEQ ID NO: 3., 'wherein'}2. The antibody according to claim 1 , whereinthe antibody is capable of binding to an intramolecular protein of a type-A influenza virus.3. The antibody according to claim 1 , whereinthe antibody is a single-domain antibody.4. The antibody according to claim 1 , whereinthe type-A influenza virus is at least one selected from the group consisting of type-A influenza virus subtypes H1N1l(A/Hyogo/YS/2011 pdm), H1N1 (A/Hokkaido/6-5/2014 pdm), H5N1 (A/duck/Hokkaido/Vac-3/2007), H7N7 (A/duck/Hokkaido/Vac-2/2004), H1N1 (A/Puerto Rico/8/34/Mount Sinai), H1N1 (A/duck/Tottori/723/1980), H1N1 (A/swine/Hokkaido/2/81), H2N3 (A/duck/Hokkaido/17/01), H2N9 (A/duck/Hong Kong/278/78), H3N2 (A/duck/Hokkaido/5/77), H3N8 (A/duck/Mongolia/4/03), H4N6 (A/duck/Czech/56), H5N2 (A/duck/Pennsylvania/10218/84), H5N3 (A/duck/Hong Kong/820/80), 116N5 (A/shearwater/S. Australia/1/72), H7N2 (A/duck/Hong Kong/301/78), H7N7 (A/seal/Massachusetts/1/1980), H9N2 (A/duck/Hong Kong/448/78), H9N2 (A/turkey/Wisconsin/1966), H, 1N6 (A/duck/England/1/1956), and H12N5 (A/duck/Alberta/60/76).5. The antibody according to claim 1 , whereinthe FR1 includes the amino acid sequences represented by SEQ ID NO: 4;the FR2 includes the amino acid sequences represented by SEQ ID NO: 5;the FR3 includes ...

Подробнее
Номер записи: 76
28-01-2021 дата публикации

ELISA KIT FOR CLOSTRIDIUM NOVYI TYPE B

Номер: US20210025889A1
Автор: CHAI Tongjie, MENG Dezhi, WEI Liangmeng
Принадлежит:

The present invention discloses an enzyme-linked immunosorbent assay (ELISA) kit for type B that adopts a suspension of type B as a coating antigen. The suspension of type B is prepared by the following method: type B is inoculated into a medium for enrichment cultivation; the resulting type B culture is centrifuged to collect bacteria; and the bacteria are washed and resuspended with carbonate buffer to obtain a suspension of type B. The kit of the present invention, which adopts intact bacteria as a coating antigen, can detect whether there are anti-antibodies in a sheep serum, with high sensitivity and specificity, and thus determine whether the sheep develops black disease. The present invention has detection results of strong specificity and excellent repeatability. 1Clostridium novyiClostridium novyi. An enzyme-linked immunosorbent assay (ELISA) kit for type B , wherein the ELISA kit uses a suspension of type B as a coating antigen.2Clostridium novyi. The ELISA kit according to claim 1 , wherein the suspension of type B is prepared by the following method:{'i': Clostridium novyi', 'Clostridium novyi', 'Clostridium novyi, 'type B is inoculated into an enrichment medium for cultivation; the resulting type B culture is centrifuged to collect bacteria; and the bacteria are washed and resuspended with carbonate buffer to obtain a suspension of type B.'}3. The ELISA kit according to claim 2 , wherein the enrichment medium is prepared by the following method:10 g of tryptone, 10 g of yeast extract powder, 5 g of potassium phosphate, 10 g of glucose and 12 g of dried meat particles are dissolved in 1,000 mL of distilled water, and the resulting solution is sterilized at 120° C. for 15 min to obtain a basic medium;1 g of vitamin K1 is dissolved in 99 ml of absolute ethanol, and the resulting solution is sterilized by filtration to obtain a vitamin K1 solution;0.5 g of heme is dissolved in 1 mL of 1 mol/L sodium hydroxide solution, then distilled water is added to ...

Подробнее
Номер записи: 77
29-01-2015 дата публикации

Immunization against clostridium difficile disease

Номер: US20150030612A1
Автор: Paul J. Giannasca, Thomas P. Monath, Wende Lei, William D. Thomas, Jr., Zhenxi Zhang
Принадлежит: Sanofi Pasteur Biologics LLC

The invention provides active and passive immunization methods for preventing and treating Clostridium difficile infection, which involve percutaneous administration of C. difficile toxin-neutralizing polyclonal immune globulin, C. difficile toxoids, or combinations thereof. Also provided by the invention are C. difficile toxoids, C. difficile toxin-neutralizing polyclonal immune globulin, and methods of identifying subjects that produce C. difficile toxin-neutralizing polyclonal immune globulin.

Подробнее
Номер записи: 78
01-02-2018 дата публикации

METHODS OF IDENTIFYING BACTERIA COMPRISING BINDING POLYPEPTIDES

Номер: US20180030434A1
Автор: Dillon Michael, Lombana Twyla Noelle, MCKENNA Rebekah, Spiess Christoph, VEERAVALLI Karthik
Принадлежит:

The invention provides methods of identifying bacteria comprising binding polypeptides. The invention also provides methods of identifying bacteria with improved expression of binding polypeptides. The invention also provides methods of identifying binding polypeptides with improved expression. The invention also provides engineered bacteria suitable for use in the methods of the invention. The invention also provides compositions that can be obtained using the methods, for example, anti-interleukin-13 (IL-13) antibodies with improved expression and/or stability. The invention also provides libraries comprising binding polypeptide (e.g., antibody) variants. 1. A method for identifying a bacterium comprising a binding polypeptide that specifically binds a target molecule , the method comprising the steps of:(a) providing a bacterium having an outer membrane permeable to a molecule having a molecular weight greater than 10 kDa, the bacterium expressing a nucleic acid encoding a candidate binding polypeptide, wherein the candidate binding polypeptide is present within the periplasm of the bacterium;(b) contacting the bacterium with a detectably labeled target molecule; and(c) identifying the bacterium as comprising a binding polypeptide by the presence of the labeled target molecule within the periplasm, wherein the bacterium remains viable following step (c).2. A method for identifying a bacterium with improved expression of a binding polypeptide that specifically binds a target molecule , the method comprising the steps of:(a) providing a bacterium having an outer membrane permeable to a molecule having a molecular weight greater than 10 kDa, the bacterium expressing a nucleic acid encoding a binding polypeptide, wherein the binding polypeptide is present within the periplasm of the bacterium;(b) contacting the bacterium with a detectably labeled target molecule; and(c) identifying the bacterium as having improved expression of the binding polypeptide by the presence ...

Подробнее
Номер записи: 79
02-02-2017 дата публикации

COMPOSITIONS AND METHODS RELATING TO LYME DISEASE

Номер: US20170030911A1
Автор: JOHNSON Barbara J.B., Russell Theresa M.
Принадлежит:

Compositions and methods of the present invention relating to HtrA sensu lato (BbHtrA) protease activity, its substrates, cleavage products, biological effects and use in detection, diagnosis and/or treatment of Lyme disease are provided. 1. A method of aiding in the diagnosis , assessment and/or treatment of Lyme disease , comprising:{'i': Borrelia burgdorferi', 'Borrelia burgdorferi, 'assaying a first sample obtained from a subject having, or suspected of having, Lyme disease for one or more peptides produced by proteolytic activity of sensu lato HtrA on at least one host protein substrate, to produce an assay result wherein detection of the one or more peptides is indicative of an active sensu lato infection in the subject.'}2. The method of claim 1 , further comprising:{'i': 'Borrelia burgdorferi', 'assaying a second sample obtained from the subject having, or suspected of having, Lyme disease to detect at least one inflammatory cytokine or chemokine selected from: CXCL1, CCL1, sICAM-1, IL-6, IL-8, CCL2, and CCL5, wherein detection of the one or more peptides in combination with an increase in CXCL1, CCL1, sICAM-1, IL-6, IL-8, CCL2, and CCL5 compared to a standard is indicative of an active sensu lato infection in the subject.'}3. The method of or claim 1 , further comprising:assaying a second sample obtained from the subject having, or suspected of having, Lyme disease for 1, 2, 3, 4, 5 6 or 7 inflammatory cytokines and chemokines selected from: CXCL1, CCL1, sICAM-1, IL-6, IL-8, CCL2, and CCL5; and{'i': 'Borrelia burgdorferi', 'assaying the second sample obtained from the subject having, or suspected of having, Lyme disease for least one inflammatory cytokine or chemokine selected from: C5a, CD40 ligand, G-CSF, GM-CSF, IFN-g, IL-1a, IL-1b, IL-ra, IL-2, IL-4, IL-5, IL-10, IL-12p70, IL-13, IL-16, IL-17, IL-17E, IL-23, IL-27, IL-32a, CXCL10, CXCL11, MIF, CCL3, CCL4 and Serpin E1; wherein an increase in 1, 2, 3, 4, 5 6 or 7 of CXCL1, CCL1, sICAM-1, IL-6, IL-8, CCL2 ...

Подробнее
Номер записи: 80
04-02-2016 дата публикации

Haptenes and Conjugates Derived from Pyocyanin, Antibodies Thereof, and Immunichemical Method for Detecting Infections Caused by Pseudomonas Aeruginosa

Номер: US20160033489A1
Автор: Antonio Pedro Villaverde Corrales, Carme PASTELLS DÍEZ, Escarlata RODRÍGUEZ CARMONA, Francisco Sanchez Baeza, María Pilar Marco Colas, Nuria PASCUAL DURÁN
Принадлежит: Universitat Autonoma de Barcelona UAB

The present invention relates to a compound of general formula I and to the use thereof as a hapten. An object of the present invention is also a conjugate of said compound I with a carrier protein or fragment thereof, with a detectable labelling agent, or with a polymer or support, and to the use thereof for producing antibodies. Furthermore, the present invention also relates to a method for the detection and/or quantification of 1-hydroxyphenazine and/or pyocyanin using said antibodies and conjugates for the detection of infections caused by Pseudomonas aeruginosa.

Подробнее
Номер записи: 81
04-02-2016 дата публикации

METHOD OF CAPTURING BACTERIA ON POLYLYSINE-COATED MICROSPHERES

Номер: US20160033503A1
Автор: Hulle Carl, Jablonski Edward
Принадлежит:

The present disclosure relates to compositions, methods, and kits for the detection, separation and/or isolation of microorganisms. Specifically, the disclosure relates to compositions, methods, and kits for using polylysine-coated particles to capture microorganisms such as bacteria. 2. The synthetic polymer of claim 1 , wherein the linker is succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (sSMCC).3. The synthetic polymer of claim 1 , wherein the solid support comprises microspheres.4. The synthetic polymer of claim 3 , wherein the microspheres comprise a coating of human serum albumin.5. A method for capturing microorganisms in a test sample comprising:a) adding a synthetic polymer microsphere having a comprising repeating monomer units of polylysine to a solution comprising the microorganisms and a fluorescent stain;b) agitating the mixture from step a) followed by incubation;c) washing the mixture from step b) by centrifugation;d) removing the microspheres from step c); ande) visually inspecting the microspheres from step d) for the presence of any colony forming units.6. The method of claim 5 , wherein the microorganisms are gram positive bacteria.7. The method of claim 5 , wherein the microorganisms are gram negative bacteria.8Staphylococcus epidermidis, Streptococcus gallolyticus, Escherica coliProteus mirabilis.. The method of claim 5 , wherein the microorganisms are selected from claim 5 , and9. The method of claim 5 , wherein the linker is succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (sSMCC).10. The method of claim 5 , wherein the fluorescent stain is a green fluorescent nucleic acid stain.11. The method of claim 5 , wherein the solid support comprises microspheres.12. The method of claim 11 , wherein the microspheres comprise a coating of human serum albumin.14. The process of claim 13 , wherein the deprotecting agent is hydroxylamine hydrochloride.15. A method of detecting a species in a sample claim 13 , comprising the steps ...

Подробнее
Номер записи: 82
01-02-2018 дата публикации

METHOD FOR ASSESSING RISK OF HUMAN CYTOMEGALOVIRUS ACTIVE INFECTION IN BODY AND RELATED KIT

Номер: US20180031556A1
Автор: GE Shengxiang, Huang Xi, LI Jinjie, LI Tingdong, Xia Ningshao, ZHANG JUN
Принадлежит:

The invention belongs to the fields of medicine and immunology, particularly, the field of immunological diagnosis. In particular, the invention discloses a method for assessing whether a subject is at risk of developing human cytomegalovirus (HCMV) active infection and a kit therefore. The method comprises the steps of: (1) determining the level of an antibody against a HCMV protein in a body fluid sample from the subject; and (2) comparing the level with a predetermined reference value, wherein if the level is below the predetermined reference value, the subject is determined to be at risk of developing HCMV active infection. In addition, the invention also discloses a method for screening a candidate drug which is capable of improving the ability of a subject to resist human cytomegalovirus (HCMV) active infection, and a kit therefore. 19-. (canceled)10. A method for assessing whether a subject is at risk of developing human cytomegalovirus (HCMV) active infection , comprising the following steps of:(1) determining the level of an antibody against a HCMV protein in a body fluid sample from the subject; and(2) comparing the level with a predetermined reference value;wherein, the HCMV protein is selected from pp150 and/or pp28; and if the level is below the reference value, the subject is determined to be at risk of developing HCMV active infection.11. The method of claim 10 , wherein the method is characterized by one or more of the following items:(a) the subject is human;(b) the body fluid sample is selected from blood, serum, plasma, urine and saliva;(c) the active infection is a primary infection by HCMV in a subject that has not been infected by HCMV, or, a re-infection by HCMV or activation of latent HCMV in a subject that has been infected by HCMV;(d) the level of the antibody against the HCMV protein in the body fluid sample is determined by immunologic assay;(e) the level refers to an antibody titer, and the reference value refers to a predetermined ...

Подробнее
Номер записи: 83
01-02-2018 дата публикации

METHODS FOR SCREENING COMPOUNDS FOR TREATING OR PREVENTING A VIRAL INFECTION OR A VIRUS-RELATED CONDITION

Номер: US20180031557A1
Автор: Campos Noëlie, FORNARELLI Pauline, Garcel Aude, Mahuteau Florence, Najman Romain, Scherrer Didier, Tazi Jamal, VAUTRIN Audrey
Принадлежит:

The present invention relates to a method for screening a compound useful for treating or preventing a viral infection or a virus-related condition in an individual, comprising at least the steps of: a) determining the ability of a candidate compound to promote the interaction between CBP20 and CBP80 in a sample, and b) selecting the candidate compound that is determined to promote said interaction at step a). The present invention further relates to a method for screening a compound useful for treating or preventing a viral infection or virus-related condition in an individual, comprising at least the steps of: a) determining the ability of a candidate compound to interact with CBP20 or CBP80 in a sample, and b) selecting the candidate compound that is determined to interact with CBP20 or CBP80 at step a). 1. A method for screening a compound useful for treating or preventing a viral infection or a virus-related condition in an individual , comprising at least the steps of:a) determining ability of a candidate compound to promote an interaction between Cap-Binding Protein 20 (CBP20) and Cap-Bind Protein 80 (CBP 80) in a sample, andb) selecting the candidate compound that is determined to promote said interaction at step a).2. (canceled)3. The method according to claim 1 , comprising at least a step of a1) measuring ability of a candidate compound to promote the interaction between CBP20 and CBP80 in said sample.4. (canceled)5. The method according to claim 1 , comprising a step of determining the ability of the compound to interact with CBP20 in a sample.6. The method according to claim 1 , comprising a step of determining the ability of the compound to interact with a fragment of CBP20 which binds to CBP80.7. The method according to claim 1 , wherein the fragment of CBP20 includes SEQ ID No 2.8. The method according to claim 1 , further comprising a step of determining ability of the candidate compound to not interact with the cap binding site of CBP20 claim 1 , ...

Подробнее
Номер записи: 84
17-02-2022 дата публикации

DEVICE AND METHOD FOR MEASUREMENT OF SARS-CoV-2 SPECIFIC ANTIGEN IN A BIOLOGICAL SAMPLE

Номер: US20220050101A1
Автор: Bhat Navakanta, Kumar Vinay
Принадлежит: PATHSHODH HEALTHCARE PVT. LTD.

A device for retaining a biological sample, for measuring a concentration of a SARS-CoV2 specific antigen, with SARS-CoV2 antigen-specific and electrochemically active immunoreceptor that is conjugated with an electrochemically active substance and optionally including an electrode reactivity enhancement agent and antibody stabilization agent. The immunoreceptor is configured to be in chemical contact with electrodes and a biological sample with SARS-CoV2 specific antigen of the device. The present invention also provides a device holder for holding the device of the present invention and a point-of-care biosensor. A method for measuring a concentration of SARS-CoV2 specific antigen from a reduced volume of biological sample is also provided in the presence of the antigen-specific and electrochemically active immunoreceptor, by measuring a peak value of redox current of the SARS-CoV2 antigen-specific and electrochemically active immunoreceptor and determining a concentration of SARS-CoV2 specific antigen in the biological sample, by linearly matching with a corresponding reference redox current. 1100. A device for collecting and retaining a biological sample , for measuring a concentration of a SARS-CoV2 specific antigen in a biological sample , comprising:{'b': ['102', '102', '101'], 'i': ['a', 'b'], '#text': '(i) at least a pair of conductive tracks , are disposed on a substrate ;'}{'b': ['103', '103', '102', '102'], 'i': ['a', 'b', 'a', 'b'], '#text': '(ii) at least a pair of electrodes , are connected to the at least pair of conductive tracks , ; and'}{'b': ['105', '103', '103'], 'i': ['a', 'b'], '#text': '(iii) a SARS-CoV2 antigen-specific and electrochemically active immunoreceptor that is conjugated with at least an electrochemically active substance, is configured to be in chemical contact with the at least pair of electrodes , and the biological sample.'}2100. The device as claimed in claim 1 , wherein the material for the substrate is a rigid material ...

Подробнее
Номер записи: 85
17-02-2022 дата публикации

Lateral Flow Device for Detecting SARS-CoV-2 Antibodies in Human and Animal Samples

Номер: US20220050102A1
Автор: Eric T. Baima, James P. Gillies, Jason J. WORKMAN, Joshua T. LIZER, Rajesh K. Mehra
Принадлежит: Zoetis Services LLC

The invention provides a lateral flow device and methods for the detection of antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a sample of bodily fluid of an animal or human. The test methods include contacting the sample with a conjugate comprising a recombinant SARS-CoV-2 spike protein antigen that has been conjugated to a detection agent, wherein an antigen-antibody complex is formed between the SARS-CoV-2 spike protein antigen conjugate and SARS-CoV-2 antibodies present in the sample; capturing the formed antigen-antibody complex with an Fc-binding molecule; and detecting the captured complex.

Подробнее
Номер записи: 86
30-01-2020 дата публикации

SOLUBLE AND IMMUNOREACTIVE VARIANTS OF HTLV CAPSID ANTIGEN P24

Номер: US20200033342A1
Автор: Faatz Elke, MUENCH Peter, Scholz Christian
Принадлежит:

The invention concerns soluble and antigenic HTLV p24 variants that can be fused to chaperones and their use in diagnostic applications such as immunoassays for detecting antibodies against HTLV-I or HTLV-II in an isolated biological sample. In particular, the invention relates to a soluble HTLV-I or HTLV-II p24 antigen comprising either the N- or the C-terminal domain of p24 and lacking the other domain. Moreover, the invention covers recombinant DNA molecules encoding these HTLV-I and -II fusion antigens as well as their recombinant production using expression vectors and host cells transformed with such expression vectors. In addition, the invention focuses on compositions of these HTLV p24 antigens with HTLV gp21 antigen and on an immunoassay method for detection of HTLV antibodies using the antigens of the invention. Also the use of HTLV p24 antigens in an in vitro diagnostic assay as well as a reagent kit for detection of anti-HTLV-antibodies comprising said HTLV antigens is encompassed. 111.-. (canceled)12. A soluble HTLV p24 antigen comprising an N-terminal domain (NTD) of HTLV p24 selected from the group consisting of SEQ ID NO. 2 and SEQ ID NO. 6 wherein said HTLV p24 antigen lacks the C-terminal domain (CTD) selected from the group consisting of SEQ ID NO. 3 and in SEQ ID NO. 7; and is fused to an oligomeric chaperone.13. The soluble HTLV p24 antigen according to claim 12 , wherein the oligomeric chaperone is selected from the group consisting of Skp and FkpA.14. A composition of HTLV antigens comprising an HTLV p24 antigen according to and an HTLV gp21 antigen comprising an amino acid sequence according to SEQ ID NO:25 claim 12 , wherein said HTLV p24 antigen and said HTLV gp21 antigen are expressed as separate polypeptides.151. A method of producing a soluble and immunoreactive HTLV p24 antigen claim 12 , said method comprising the steps of culturing host cells transformed with an expression vector comprising operably linked a recombinant DNA molecule ...

Подробнее
Номер записи: 87
30-01-2020 дата публикации

DETECTION METHODS EMPLOYING HCV CORE LIPID AND DNA BINDING DOMAIN MONOCLONAL ANTIBODIES

Номер: US20200033344A1
Автор: AHLBERG APRIL, BRANCH ANDREA, ENG FRANCIS, HAWKSWORTH DAVID, MAROHNIC CHRISTOPHER, Muerhoff A. Scott, OTIS KATHY, TIEMAN BRYAN, Ziemann Robert
Принадлежит:

The present disclosure provides detection methods employing HCV core lipid binding domain and DNA binding domain monoclonal antibodies or antibody fragments. In certain embodiments, the lipid binding domain monoclonal antibody or antibody fragment recognizes an epitope in amino acids 141 to 161 of HCV core protein and the DNA binding domain antibody or antibody fragment recognizes an epitope in amino acids 95-123 (e.g., in amino acids 99-117) of HCV core protein. 116.-. (canceled)17. A system comprising:(a) a first antibody, or antigen-binding portion thereof, which comprises heavy chain CDR1, CDR2, and CDR3 amino acid sequences of SEQ ID NO: 588, SEQ ID NO: 589, and SEQ ID NO: 590, respectively, and light chain CDR1, CDR2, and CDR3 amino acid sequences of SEQ ID NO: 585, SEQ ID NO: 586, and SEQ ID NO: 587; and(b) a second antibody, or antigen-binding portion thereof, which specifically binds to the amino acid sequence of SEQ ID NO: 574 in the lipid binding domain of HCV core protein.1821.-. (canceled)22. The system of claim 17 , wherein the first and/or second antibody claim 17 , or the antigen-binding portion thereof claim 17 , comprises a detectable label attached thereto.23. A kit comprising:(a) a first antibody, or antigen-binding portion thereof, which comprises heavy chain CDR1, CDR2, and CDR3 amino acid sequences of SEQ ID NO: 588, SEQ ID NO: 589, and SEQ ID NO: 590, respectively, and light chain CDR1, CDR2, and CDR3 amino acid sequences of SEQ ID NO: 585, SEQ ID NO: 586, and SEQ ID NO: 587;(b) a second antibody, or antigen-binding portion thereof, which specifically binds to the amino acid sequence of SEQ ID NO: 574 in the lipid binding domain of HCV core protein; and(c) instructions for detecting an HCV core protein in a sample.24. The kit of claim 23 , wherein the first and/or second antibody claim 23 , or the antigen-binding portion thereof claim 23 , comprises a detectable label attached thereto. The present application is a divisional of copending U.S. ...

Подробнее
Номер записи: 88
04-02-2021 дата публикации

An immunoassay for the diagnosis of viral infections

Номер: US20210033609A1
Автор: Andrea DEERBERG, Christiane Radzimski, Erik LATTWEIN, Jana BÖTHFÜR, Katja STEINHAGEN
Принадлежит: EUROIMMUN Medizinische Labordiagnostika AG

A recombinant polypeptide can be used in the diagnosis of the presence of a Zika virus in a patient. The recombinant polypeptide includes SEQ ID NO: 1 or a variant thereof. The recombinant peptide may be a monomer, a dimer, or a hexamer.

Подробнее
Номер записи: 89
08-02-2018 дата публикации

ANTIBODY MOLECULES AND USES THEREOF

Номер: US20180037640A1
Автор: Erwig Lars-Peter, Gow Neil Andrew Robert, Jensen Allan, Rudkin Fiona Marion
Принадлежит: THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN

This invention relates to recombinant human antibody molecules. The antibodies bind fungal antigens, for example from spp. Human antibody encoding genes targeting clinically relevant epitopes have been isolated from single B cells from carefully selected donors and screened with specified types of protein or cell wall extract. The panel of purified, fully human recombinant IgG1 mAbs generated displayed a diverse range of specific binding profiles and demonstrated efficacy in a disease model. The fully human mAbs and derivatives thereof have utility in the generation of diagnostics, therapeutics and vaccines. 13.-. (canceled)4Candida. An anti-recombinant human antibody molecule which comprises a VH domain comprising(i) an HCDR3 having the amino acid sequence of SEQ ID NO: 6x or the sequence of SEQ ID NO: 6x with 1, 2, or 3 amino acid substitutions, deletions or insertions; and optionally(ii) an HCDR2 having the amino acid sequence of SEQ ID NO: 4x or the sequence of SEQ ID NO: 4x with 1, 2, or 3 amino acid substitutions, deletions or insertions; and optionally 'wherein ‘x’ is one letter from A to R, and said sequence is as shown in Table ‘x’ herein.', '(iii) an HCDR1 having the amino acid sequence of SEQ ID NO: 2x or the sequence of SEQ ID NO: 2x with 1, 2 or 3 amino acid substitutions, deletions or insertions,'}5. (canceled)6. (canceled)7. An antibody molecule according to wherein the antibody molecule comprises a VH domain comprising a HCDR1 claim 4 , a HCDR2 and a HCDR3 having the sequences of SEQ ID NOs 2x claim 4 , 4x and 6x respectively.8. An antibody molecule according to wherein the antibody molecule comprises a VH domain comprising one or more or all of a FW1 claim 7 , a FW2 claim 7 , a FW3 and a FW4 having the sequences of SEQ ID NOs 1x claim 7 , 3x claim 7 , 5x and 7x respectively.9. An antibody molecule according to wherein the antibody molecule comprises a VH domain having an amino acid sequence at least about 80% identical to SEQ ID NO: 15x and\or ...

Подробнее
Номер записи: 90
09-02-2017 дата публикации

SIGNAL AMPLIFICATION IN SOLUTION-BASED PLASMONIC SPECIFIC-BINDING PARTNER ASSAYS

Номер: US20170038366A1
Автор: Aron Kenneth, CHIANG Vincent, FRISZ Jessica, Mehra Rajesh
Принадлежит:

The present invention relates to analyte detection devices and methods of using such devices to detect minute quantities of a target analyte in a sample. In particular, the invention provides a method of detecting a target analyte in a sample comprising mixing the sample with a first detection conjugate and a second detection conjugate in solution, wherein the first and second detection conjugates comprise metallic nanostructures coupled to binding partners that are capable of specifically binding to the target analyte if present in the sample to form a complex between the first detection conjugate, the analyte, and the second detection conjugate, wherein a change in an optical signal upon complex formation indicates the presence of the target analyte in the sample. Methods of preparing nanostructures and nanoalloys, as well as nanostructures and nanoalloys conjugated to binding partners, are also described. 1. A method of detecting a target analyte in a sample comprising:(a) mixing the sample with a first detection conjugate and a second detection conjugate, wherein the first and second detection conjugates comprise composite metallic nanostructures coupled to binding partners that are capable of specifically binding to the target analyte if present in the sample to form a complex between the first detection conjugate, the analyte, and the second detection conjugate;(b) exposing the complex to a light source at a wavelength range within the ultraviolet-visible-infrared spectrum; and(c) measuring an optical signal from the complex, wherein a change in the optical signal indicates the presence of the target analyte in the sample.2. The method of claim 1 , wherein the optical signal is reflectance claim 1 , an absorbance spectrum claim 1 , scattering spectrum claim 1 , or an emission spectrum.3. The method of claim 1 , wherein the change in the optical signal comprises a spectral peak wavelength shift and/or a total spectral wavelength shift.4. The method of claim 3 , ...

Подробнее
Номер записи: 91
08-02-2018 дата публикации

DIAGNOSTIC METHOD FOR PEDIATRIC ACUTE-ONSET NEUROPSYCHIATRIC SYNDROME (PANS) AND PEDIATRIC AUTOIMMUNE NEUROPSYCHIATRIC DISORDER ASSOCIATED WITH STREPTOCOCCI INFECTION (PANDAS)

Номер: US20180038870A1
Автор: Cunningham Phina Madeleine, Kirvan Christine, Shimasaki Craig David, Swedo Susan E.
Принадлежит:

The present invention provides a panel of at least five clinical analyses or tests (using serum samples) to determine the risk of pediatric acute-onset neuropsychiatric syndrome (PANS) and/or pediatric autoimmune neuropsychiatric disorder associated with streptococcal infection (PANDAS) in an individual. These include enzyme linked immunosorbent assays (ELISAs) to measure antibody titers against neuronal antigens present in the brain; the neuronal antigens include lysoganglioside, tubulin, dopamine receptor D1, dopamine receptor D2, serotonin receptor 5HT2A, and serotonin receptor 5HT2C. Antibody titers against at least four of these neuronal antigens are required in the present methods; preferably antibody tiers against all of these neuronal antigens are measured. A final assay is used to quantify calcium/calmodulin-dependent protein kinase activity using a neuronal cell line. The results of these analyses or tests are then combined using an algorithm to determine whether a PANS or PANDAS diagnosis is appropriate for the individual. Depending on the diagnosis, an appropriate treatment can be determined. 1. (canceled)2. A method of analyzing a sample from a patient , comprising:a) providing a surface comprising at least four molecules selected from lysoganglioside, tubulin, dopamine receptor D1, dopamine receptor D2, human serotonin receptor 5HT2A, and human serotonin receptor 5HT2C, wherein the at least four molecules are immobilized on the surface;b) contacting the surface with the sample to form at least four antibody/molecule complexes on the surface, the at least four antibody/molecule complexes selected from anti-lysoganglioside antibody/lysoganglioside complex, anti-tubulin antibody/tubulin complex, anti-dopamine receptor D1 antibody/dopamine receptor D1 complex, anti-dopamine receptor D2 antibody/dopamine receptor D2 complex, anti-human serotonin receptor 5HT2A antibody/human serotonin receptor 5HT2A complex, and anti-human serotonin receptor 5HT2C antibody/ ...

Подробнее
Номер записи: 92
07-02-2019 дата публикации

OIL-BASED ADJUVANTS

Номер: US20190038737A1
Автор: Dominowski Paul Joseph, Foss Dennis L., Gallo Guillermo, Hardham John Morgan, Krebs Richard Lee, Lightle Sandra Ann Marie, Mahan Suman, Mediratta Sangita, Mohr Kaori, Mwangi Duncan, Rai Sharath K., Salmon Sarah A., Vora Shaunak, Wilmes Lauren
Принадлежит:

The instant invention provides various formulations comprising combinations of immunostimulating oligonucleotides, polycationic carriers, sterols, saponins, quaternary amines, TLR-3 agonists, glycolipids, and MPL-A or analogs thereof in oil emulsions, use thereof in preparations of immunogenic compositions and vaccines, and use thereof in the treatment of animals. 1. An adjuvant formulation comprising an oily phase and an aqueous phase , wherein the oily phase comprises at least 20% of the formulation v/v , wherein said formulation comprises at least one of monophosphoryl lipid A (MPL-A) or an analog thereof and an immunostimulatory oligonucleotide , with provisos that: i. a poly I:C, a glycolipid, and, optionally, a quaternary amine; or', 'ii. a polycationic carrier;, 'a) if said immunostimulatory oligonucleotide is absent, then the formulation comprisesb) if said monophosphoryl lipid A (MPL-A) or the analog thereof is absent, then the formulation comprises a source of aluminum.2. The adjuvant formulation of claim 1 , whereinthe immunostimulatory oligonucleotide, if present, is a CpG or an oligoribonucleotide;the polycationic carrier, if present, is selected from the group consisting of dextran, dextran DEAE (and derivatives thereof), PEGs, guar gums, chitosan derivatives, polycellulose derivatives like hydroxyethyl cellulose (HEC) polyethylenimene, poly aminos; andthe quaternary amine, if present, is selected from the group consisting of DDA and avridine.4. The adjuvant formulation of claim 3 , wherein the glycolipid is N-(2-Deoxy-2-L-leucylamino-β-D-glucopyranosyl)-N-octadecyldodecanoylamide or a salt thereof.5. The adjuvant formulation of claim 1 , comprising both said monophosphoryl lipid A (MPL-A) or the analog thereof claim 1 , and further comprising at least one of a sterol and a poly I:C.6. The adjuvant formulation of claim 5 , comprising the sterol and further comprising a saponin.7. The adjuvant formulation of comprising the poly I:C claim 1 , and further ...

Подробнее
Номер записи: 93
12-02-2015 дата публикации

Methods for detection of anti-cytomegalovirus neutralizing antibodies

Номер: US20150044668A1
Автор: Barthelemy ONTSOUKA, David E. Anderson, Jasminka Bozic
Принадлежит: Variation Biotechnologies Inc

The present disclosure provides methods useful for determining levels of HCMV infection in host cells and, by extension, determining levels of neutralizing antibodies present in a sample. The present disclosure encompasses the recognition that HCMV viruses that have a fluorescent moiety permit detection of viral infection (e.g., by assessing fluorescence in cells after contacting the host cell with the virus). In some embodiments, levels of HCMV infection are determined by fluorescence detection where the virus has been preincubated with a test sample (e.g., a serum sample) from a subject. In some embodiments, the subject has been administered a candidate HCMV vaccine.

Подробнее
Номер записи: 94
12-02-2015 дата публикации

Diagnostic Test for Infectious Diseases in Cattle

Номер: US20150044689A1
Автор: Gutierrez Ordonez Ana Paola, LICEA NAVARRO Alexei Fedorovish, Olivares Quintero Jose Felix
Принадлежит:

The invention relates to an isolated or recombinant protein from the shark , which has bovine-erythrocyte-recognition activity and which can bind to sequences of antigens and/or proteins that are characteristic of infectious diseases. Once the aforementioned protein is bound to specific antigens of infectious diseases, it can haemagglutinate upon recognizing the bovine erythrocytes and antibodies characteristic of said diseases, which are present in the active state in biological samples such as whole blood, plasma or serum of bovine origin. The invention also relates to methods for protecting the detection of antibodies characteristic of infectious diseases, using the purified periplasmic extract or fusion protein, optionally purifying the recombinant protein. 1Heterodontus francisci. A nucleic acid fragment obtained from shark , comprising the sequence SEQ ID NO: 1.2. The fragment of claim 1 , wherein the fragment encodes a protein with sequence SEQ ID NO: 2.3. The fragment of claim 2 , wherein the protein recognizes bovine erythrocytes.4. The fragment of claim 2 , wherein the fragment allows the fusion of the gene and the protein with sequences of infectious disease antigens.5Heterodontus francisci. An isolated protein from shark claim 2 , wherein the isolated protein contains the sequence SEQ ID NO: 2.6. The isolated protein of claim 5 , wherein the isolated protein recognizes bovine erythrocytes.7. The isolated protein of claim 6 , wherein at least 85% of the nucleotide sequence of the isolated protein is the same as the sequence SEQ ID NO: 1 to recognize bovine erythrocytes.8. The isolated protein of claim 5 , wherein the fusion protein can be fused with infectious diseases antigens.9Heterodontus francisci. A method for obtaining a recombinant protein from shark claim 5 , comprising the following steps:{'i': 'Heterodontus francisci', 'a) obtaining a (non-immune) library of shark antibodies;'}{'i': 'Escherichia coli,', 'b) cloning the library in'} i) the ...

Подробнее
Номер записи: 95
07-02-2019 дата публикации

VACCINE AND METHODS FOR DETECTING AND PREVENTING FILARIASIS

Номер: US20190040108A1
Автор: KALYANASUNDARAM Ramaswamy
Принадлежит:

The present invention is a multivalent vaccine for immunizing an animal against filariasis. In some embodiments, the antigens of the multivalent vaccine are protein-based, DNA-based, or a combination thereof. This invention also provides a method and kit for detecting a filarial nematode and determining vaccine efficacy. 1. A fusion protein comprising{'i': 'Brugia malayi', '(a) Abundant Larval Transcript; and'}{'i': Brugia malayi', 'Brugia malayi', 'Brugia malayi, '(b) Small heat shock protein 12.6, Tetraspanin, Thioredoxin Peroxidase 2, or a combination thereof.'}2. The fusion protein of claim 1 , wherein the Abundant Larval Transcript comprises SEQ ID NO:78 or SEQ ID NO:79; the Small heat shock protein 12.6 comprises SEQ ID NO:80 or SEQ ID NO:81; the Tetraspanin comprises SEQ ID NO:82; and the Thioredoxin Peroxidase 2 comprises SEQ ID NO:83 or SEQ ID NO:84.3. The fusion protein of claim 1 , wherein the Abundant Larval Transcript comprises SEQ ID NO:37 or SEQ ID NO:39; the Small heat shock protein 12.6 comprises SEQ ID NO:49 or SEQ ID NO:64; the Tetraspanin comprises SEQ ID NO:45 claim 1 , SEQ ID NO:63 or SEQ ID NO:77; and the Thioredoxin Peroxidase 2 comprises SEQ ID NO:71.4. The fusion protein of claim 1 , wherein said protein comprises SEQ ID NO:70; SEQ ID NO:73 or SEQ ID NO:74.5. A recombinant vector encoding the fusion protein of .6. A host cell comprising the recombinant vector of .7. A vaccine comprising the fusion protein of and an adjuvant.8. A method for immunizing an animal against filariasis comprising administering to an animal in need thereof the vaccine of thereby immunizing the animal against filariasis.9. A vaccine comprising(a) an Abundant Larval Transcript protein comprising SEQ ID NO:78 or SEQ ID NO:79; and(b) a Small heat shock protein 12.6 comprising SEQ ID NO:80 or SEQ ID NO:81; a Tetraspanin protein comprising SEQ ID NO:82; a Thioredoxin Peroxidase 2 protein comprising SEQ ID NO:83 or SEQ ID NO:84, or a combination thereof.10. The vaccine of ...

Подробнее
Номер записи: 96
24-02-2022 дата публикации

SALIVA TESTING KIT USING NANO CARBON IMMUNOCHROMATOGRAPHY

Номер: US20220057390A1
Автор: Hu Xiaolong, Nogura Fahmi, Zheng Hong
Принадлежит:

Biological assay systems, methods, and devices for detecting the presence of the virus responsible for COVID-19 (sars-cov-2) in the saliva of an individual. The systems, methods, and devices utilize immunoassay technology for detecting the presence of antigen in a sample, such as the virus responsible for COVID-19 in the saliva of an individual. The immunoassay technology in accordance with embodiments of the systems, methods, and devices use nano-carbon, or carbon nanoparticles attached to biorecognition/detector molecules, such as antibodies. 1. A rapid nano-carbon immunochromatography device for screening for presence of COVID-19 virus in saliva of an individual to be tested comprising:a device configured to detect the presence of COVID virus from a saliva sample.2. The rapid nano-carbon immunochromatography device according to claim 1 , wherein said nano-carbon immunochromatography device configured to detect the presence of COVID virus from a saliva sample is a nano-carbon immunochromatography which includes carbon nanoparticles.3. The rapid nano-carbon immunochromatography device according to claim 1 , wherein said carbon nanoparticles are attached to antibodies configured to detect the presence of COVID-19 virus within said saliva sample.4. The rapid nano-carbon immunochromatography device according to claim 1 , wherein said nano-carbon immunochromatography device includes an indicator window configured to indicate the presence or absence of said COVID-19 virus within said saliva sample.5. The rapid nano-carbon immunochromatography device according to claim 4 , wherein said indicator window indicates the presence or absence of said COVID-19 virus within said saliva sample rapidly.6. A rapid nano-carbon immunochromatography device for screening for presence of COVID-19 virus in saliva of an individual to be tested comprising:an sample application pad configured for receiving or accepting a saliva sample to be analyzed for the presence or absence of said COVID- ...

Подробнее
Номер записи: 97
24-02-2022 дата публикации

DIAGNOSTIC AND THERAPEUTIC FOR THE IDENTIFICATION AND TREATMENT OF SARS-CoV-2

Номер: US20220057391A1
Автор: Kasti Maria, Neblett Charles, VLACHAKIS Dimitrios
Принадлежит:

The present invention provides methods and diagnostic kits for the detection or prediction of SARS-CoV-2. More particularly, the present invention provides for the diagnosis of SARS-CoV-2 by detecting in a human biological sample inhibition of protein translation by the phosphorylation of the eukaryotic initiation factor-2α (eIF-2α), and the formation of stress granules (SGs) known to be affected by Sars-CoV-2 1. A dual qualitative and quantitative diagnostic immunoassay device for the detection of disease in a subject comprising:(a) a dual quantitative and qualitative lateral flow immunoassay (LFIA) comprising:(b) a central opening to allow contact of the LFIA with a biological sample;(c) a first end of the LFIA comprises disease related biomarker detection following the principles of lateral flow immunoassay (LFIA) tests, wherein specific exosomal biomarkers for the disease under study are detected through the recognition of the antigens contained in the sample by a specific antibody stabilized in the strip; and(d) a second end of the device comprises exosome identification and quantification based on a quantitative LFIA, wherein specific exosome biomarkers related to the disease under study are detected through the recognition of exosomal biomarkers contained in the biological sample by an antibody stabilized in the strip, wherein the visual read-out is accordingly adjusted so that the biomarker advancement distance is proportional to an amount of detected exosome from the biological sample.2. The dual qualitative and quantitative diagnostic immunoassay of claim 1 , wherein said exosomal biomarker comprises exosomal proteins claim 1 , exosomal RNAs claim 1 , or exosomal lncRNAs.3. The dual qualitative and quantitative diagnostic immunoassay of claim 2 , wherein said exosomal biomarker is an exosomal protein selected from the group consisting of CD9 claim 2 , CD81 claim 2 , CD63 claim 2 , CD147 claim 2 , CD235 claim 2 , CD41 claim 2 , COPB2 (coat complex subunit ...

Подробнее
Номер записи: 98
18-02-2021 дата публикации

ANTIBODY AGAINST ALPHA-11 INTEGRIN AND ITS USE

Номер: US20210047418A1
Автор: AKSLEN Lars Andreas, GULLBERG Elon Donald, REED Rolf, SMELAND Hilde Ytre-Hauge
Принадлежит:

In a first aspect, the present invention relates to an antibody directed against the alpha-11 integrin subunit, in particular, said antibody is an antibody binding the same epitope as the antibody produced by the hybridoma deposited as DSM ACC3320. Further, the present invention relates to a method for detecting the alpha-11 integrin subunit in a sample. In particular, the antibody according to the present is an anti- body suitable for use in samples being cryopreserved and cryosectioned or formaldehyde fixed and paraffin embedded. The present invention relates further to a kit for detecting the alpha-11 integrin subunit containing the antibody according to the present invention. Finally, the present invention provides the antibody in a humanized form. The antibody, in particular, in its humanized forms are useful for antibody drug conjugates. 1. An antibody that binds to the same epitope of the alpha-11 integrin subunit as bound by 210 F4B6A4 produced by the hybridoma deposited as DSM ACC3320.2. The antibody of wherein the antibody is 210 F4B6A4 produced by the hybridoma deposited as DSM ACC3320.3. The antibody of or comprising the heavy and light chain complementarity determining regions (CDR) of the antibody as defined in or claim 2 , in particular claim 2 , wherein the CDR are CDR of the antibody produced by the hybridoma deposited as DSM ACC3320.5. The antibody according to any one of the preceding claims wherein the antibody is selected from the group consisting of scFv claim 2 , a Fab claim 2 , and a (Fab′).6. The antibody according to any one of the preceding claims comprising a heavy chain variable region comprising the following CDR's:a) Seq. ID No. 1;b) Seq. ID No. 2; andc) Seq. ID No. 3.7. The antibody according to wherein the heavy chain variable region comprises or consist of the amino acid sequence of Seq. ID No. 7.8. The antibody according to any one of the preceding claims comprising a light chain variable region comprising the following CDR's:a) ...

Подробнее
Номер записи: 99
18-02-2016 дата публикации

Method for Detection of Legionella Bacteria Employing Purified Antigen-Specific Antibodies

Номер: US20160047807A1
Автор: Elena V. Molokova, Norman J. Moore, Vladimir A. Koulchin
Принадлежит: Alere Scarborough Inc

The present invention involves extracting from Legionella bacteria, particularly L. pneumophila bacteria, an essentially protein-free O-polysaccharide or carbohydrate antigen, coupling this antigen to an activated chromatographic column through a protein space molecule which is first conjugated to the antigen, utilizing the column thus prepared for the affinity purification of raw polyvalent antibodies to the same Legionella bacterium from which the O-polysaccharide or carbohydrate antigen was separated—thereby obtaining antigen-specific antibodies which are useful for the rapid detection of the corresponding Legionella bacterium or its antibody in human bodily fluids such as urine, sputum, blood and the like or in environmental samples suspected of harboring the Legionella bacterium.

Подробнее
Номер записи: 100